Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares of the registrant’s common stock outstanding as of ~~May 7, 2009~~February 3, 2010 was ~~28,826,381.~~29,059,664.

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.


	April 3, 2009		October 3, 2008		January 1, 2010		October 2, 2009
ASSETS
Current assets
Cash and cash equivalents	$	130,505	$	103,895	$	229,307	$	209,348
Accounts receivable, net		156,694		199,420		147,633		159,958
Inventories		146,963		161,039		135,145		136,704
Deferred taxes		33,132		33,618		38,461		38,349
Prepaid expenses and other current assets		14,239		15,663		13,366		15,488

Total current assets		481,533		513,635		563,912		559,847
Property, plant and equipment, net		111,064		110,343		110,396		114,363
Goodwill		203,573		218,208		215,593		216,223
Intangible assets, net		29,511		36,972		26,560		28,334
Other assets		23,899		24,089		26,993		25,420

Total assets	$	849,580	$	903,247	$	943,454	$	944,187

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities
Current portion of long-term debt					$	6,250	$	6,250
Accounts payable	$	57,924	$	70,923		56,702		63,368
Deferred profit		12,252		10,957		10,561		8,935
Accrued liabilities		148,662		167,173		163,839		171,103

Total current liabilities		218,838		249,053		237,352		249,656
Long-term debt		18,750		18,750		12,500		12,500
Deferred taxes		3,320		4,341		2,718		2,505
Other liabilities		42,869		43,431		42,980		41,255

Total liabilities		283,777		315,575		295,550		305,916

Commitments and contingencies (Notes 6, 7, 9, 10, 11, 12, 13 and 16)
Commitments and contingencies (Notes 2, 6, 7, 9, 10, 11, 12 and 13)

Stockholders’ equity
Preferred stock—par value $0.01, authorized—1,000 shares; issued—none		—		—		—		—
Common stock—par value $0.01, authorized—99,000 shares; issued and outstanding—28,778 shares at April 3, 2009 and 28,917 shares at October 3, 2008		358,274		356,192
Common stock—par value $0.01, authorized—99,000 shares; issued and outstanding—29,026 shares at January 1, 2010 and 28,971 shares at October 2, 2009						371,685		368,324
Retained earnings		206,115		186,009		228,040		220,068
Accumulated other comprehensive income		1,414		45,471		48,179		49,879

Total stockholders’ equity		565,803		587,672		647,904		638,271

Total liabilities and stockholders’ equity	$	849,580	$	903,247	$	943,454	$	944,187

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.


	Six Months Ended						Fiscal Quarter Ended
	April 3, 2009			March 28, 2008			January 1, 2010			January 2, 2009
Cash flows from operating activities
Net earnings	$	23,227		$	33,371		$	8,071		$	13,041
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization		13,371			13,279			6,867			6,843
Gain on disposition of property, plant and equipment		(4	)		(298	)
Impairment of private company equity investment		—			3,018
Loss (gain) on disposition of property, plant and equipment								34			(27	)
Share-based compensation expense		4,311			4,822			1,232			2,366
Deferred taxes		(655	)		(1,656	)		408			113
Unrealized (gain) loss on currency remeasurement		(6,363	)		642
Unrealized loss (gain) on currency remeasurement								1,449			(6,686	)
Changes in assets and liabilities, excluding effects of acquisitions:
Accounts receivable, net		32,119			(1,732	)		11,505			24,570
Inventories		1,182			(23,718	)		595			(7,942	)
Prepaid expenses and other current assets		229			(992	)		2,144			(107	)
Other assets		(1,148	)		(35	)		(1,671	)		(1,029	)
Accounts payable		(9,394	)		3,287			(5,981	)		(3,618	)
Deferred profit		1,548			(4,474	)		1,651			303
Accrued liabilities		(6,900	)		3,813			(5,364	)		(15,619	)
Other liabilities		(1,013	)		405			1,791			4,723

Net cash provided by operating activities		50,510			29,732			22,731			16,931

Cash flows from investing activities
Proceeds from sale of property, plant and equipment		5,246			787			72			5,166
Purchase of property, plant and equipment		(15,137	)		(9,208	)		(2,054	)		(6,943	)
Acquisitions, net of cash acquired		(2,247	)		(15,209	)
Private company equity investments		—			(18	)
Purchase of businesses, net of cash acquired								(1,455	)		(726	)

Net cash used in investing activities		(12,138	)		(23,648	)		(3,437	)		(2,503	)

Cash flows from financing activities
Repurchase of common stock		(7,475	)		(71,523	)		(215	)		(279	)
Issuance of common stock		2,315			13,233			2,066			909
Excess tax benefit from share-based plans		—			2,963
Transfers to Varian Medical Systems, Inc.		(365	)		(422	)		(210	)		(146	)

Net cash used in financing activities		(5,525	)		(55,749	)
Net cash provided by financing activities								1,641			484

Effects of exchange rate changes on cash and cash equivalents		(6,237	)		10,692			(976	)		(1,878	)

Net increase (decrease) in cash and cash equivalents		26,610			(38,973	)
Net increase in cash and cash equivalents								19,959			13,034
Cash and cash equivalents at beginning of period		103,895			196,396			209,348			103,895

Cash and cash equivalents at end of period	$	130,505		$	157,423		$	229,307		$	116,929

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.

These unaudited interim condensed consolidated financial statements of Varian, Inc. and its subsidiary companies (collectively, the “Company”) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The October ~~3, 2008~~2, 2009 balance sheet data was derived from audited financial statements, but does not include all disclosures required in audited financial statements by U.S. GAAP. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended October ~~3, 2008~~2, 2009 filed with the SEC. In the opinion of the Company’s management, the unaudited interim condensed consolidated financial statements include all normal recurring adjustments necessary to present fairly the information required to be set forth therein. The results of operations for the ~~six months~~fiscal quarter ended ~~April 3, 2009~~January 1, 2010 are not necessarily indicative of the results to be expected for a full year or for any other periods.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

The Company designs, develops, manufactures, markets, sells and services scientific instruments (including analytical instruments, research products and related software, consumable products, accessories and services) and vacuum products (including related accessories and services). ~~The Company~~These businesses primarily ~~serves~~serve life science, environmental, energy, and applied research and other customers.

Until April 2, 1999, the business of the Company was operated as the Instruments Business of Varian Associates, Inc. (“VAI”). On that date, VAI distributed to the holders of its common stock one share of common stock of the Company and one share of common stock of Varian Semiconductor Equipment Associates, Inc. (“VSEA”), which was formerly operated as the Semiconductor Equipment business of VAI, for each share of VAI (the “Distribution”). VAI retained its Health Care Systems business and changed its name to Varian Medical Systems, Inc. (“VMS”). Transfers made to VMS under the terms of the Distribution are reflected as financing activities in the Unaudited Condensed Consolidated Statement of Cash Flows.

Merger Agreement.On July 26, 2009, the Company, Agilent Technologies, Inc., a Delaware corporation (“Agilent”), and Cobalt Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Agilent (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Merger Sub will, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, merge with and into the Company and the Company will survive the merger and continue as a wholly owned subsidiary of Agilent (the “Merger”). Pursuant to the terms of the Merger Agreement and subject to the conditions thereof, at the effective time of the Merger (the “Effective Time”), each share of common stock of the Company issued and outstanding immediately prior to the Effective Time will be converted into the right to receive $52.00 in cash, without interest.

The Company and Agilent have made certain representations, warranties and covenants in the Merger Agreement, including, among others, covenants that, subject to certain exceptions, (i) the Company will conduct

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

its business in the ordinary course consistent with past practice, and refrain from taking specified actions, during the period between the execution of the Merger Agreement and the Effective Time, (ii) the Board of Directors of the Company will recommend to its stockholders adoption of the Merger Agreement, and (iii) the Company will not solicit, initiate, seek or knowingly encourage or facilitate, any inquiry, proposal or offer from, furnish non-public information to, or participate in any discussions with, or enter into any agreement with, any person or group regarding any alternative transaction.

The Merger Agreement contains certain termination rights for both the Company and Agilent and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Agilent a termination fee of $46 million.

The Boards of Directors of the Company and Agilent approved the Merger and the Merger Agreement. In addition, concurrently with the execution of the Merger Agreement, all directors and certain executive officers of the Company, who together held less than 1% of the Company’s outstanding common stock as of July 26, 2009, entered into voting agreements whereby they agreed among other things to vote all shares of the Company’s common stock held by them in favor of the adoption of the Merger Agreement.

On October 5, 2009, the Company’s stockholders approved the Merger. The Merger remains subject to regulatory approvals and the satisfaction or waiver of certain other closing conditions.

Fiscal Periods. The Company’s fiscal years reported are the 52- or 53-week periods ending on the Friday nearest September 30. Fiscal year ~~2009~~2010 will comprise the 52-week period ending October ~~2, 2009,~~1, 2010, and fiscal year ~~2008~~2009 was comprised of the ~~53-week~~52-week period ended October ~~3, 2008.~~2, 2009. The fiscal quarters ended January 1, 2010 and ~~six months ended April 3,~~January 2, 2009 ~~and March 28, 2008~~ each comprised 13 ~~weeks and 26 weeks, respectively.~~

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~weeks.

~~Comprehensive Income.~~Subsequent Events. In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 855,Subsequent Events, the Company has evaluated subsequent events through the time the Company’s Unaudited Condensed Consolidated Financial Statements were issued on February 5, 2010.

A summary of the components of the Company’s comprehensive income (loss) ~~income~~ follows:

Effective October ~~4, 2008~~3, 2009 (the first day of fiscal year ~~2009),~~2010) the Company adopted ~~Statement of Financial Accounting Standards No. (“SFAS”) 157,~~ASC 820,Fair Value Measurements and Disclosures~~. The Company elected to delay applying SFAS 157 to~~, for certain non-recurring nonfinancial assets and nonfinancial ~~liabilities until fiscal year 2010, as permitted by FASB Staff Position (“FSP”) 157-2,~~~~Effective Date of FASB Statement No. 157~~.liabilities.

~~On the same date, the Company also adopted SFAS 159,~~~~The Fair Value Option for Financial Assets and Liabilities~~, which permits entities to elect, at specified election dates, to measure eligible financial instruments at fair value. Since its adoption of SFAS 159, the Company has not elected the fair value option for any financial assets or liabilities that were not previously measured at fair value.NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Fair Value Hierarchy.~~SFAS 157~~ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are:

Level 1—Observable inputs that reflect quoted prices for identical assets or liabilities in active markets.

Level 2—Other inputs that are directly or indirectly observable in the marketplace.

Level 3—Unobservable inputs which are supported by little or no market activity.

~~As of April 3, 2009, the Company did not have any financial liabilities that were measured at fair value on a recurring basis.~~ Financial assets measured at fair value on a recurring basis as of ~~April 3, 2009 were as~~January 1, 2010 follow:


	Fair Value Measurements Using:								Fair Value Measurements Using:
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
(in thousands)
Financial Assets:
Financial assets:
Money market funds (cash equivalents)	$	38,361	$	—	$	—	$	38,361	$	59,283	$	—	$	—	$	59,283

Total financial assets	$	38,361	$	—	$	—	$	38,361	$	59,283	$	—	$	—	$	59,283

~~VARIAN, INC. AND SUBSIDIARY COMPANIES~~The cost basis of cash and cash equivalents approximates fair value due to the short period of time to maturity.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~


	April 3, 2009		October 3, 2008		January 1, 2010			October 2, 2009
(in thousands)
Inventories
Raw materials and parts	$	69,432	$	77,447	$	60,644		$	60,222
Work in process		24,039		25,091		22,998			22,596
Finished goods		53,492		58,501		51,503			53,886

Total	$	146,963	$	161,039	$	135,145		$	136,704


Deferred profit
Revenue					$	23,808		$	20,601

Cost of sales					$	(13,247	)	$	(11,666	)

~~Effective January 3, 2009 (the first day of the second quarter of fiscal year 2009), the Company adopted SFAS 161,~~~~Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement 133.~~ The adoption of SFAS 161 had no financial impact on the Company’s primary financial statements as it only required additional footnote disclosures. The Company has applied the requirements of SFAS 161 on a prospective basis. Accordingly, disclosures related to interim periods prior to the date of adoption have not been presented.

The Company enters into foreign exchange forward contracts to minimize the short-term impact of foreign currency fluctuations on the Company’s legal entities’ monetary assets and liabilities denominated in currencies other than their functional currencies. These foreign currency exposures mainly arise from intercompany transactions ~~involving~~by and between the ~~Company’s~~parent company and its various foreign ~~subsidiaries and business units.~~subsidiaries. The Company does not designate its forward exchange contracts as hedging instruments, and these contracts do not qualify for hedge accounting treatment ~~under SFAS 133,~~~~Accounting for Derivative Instruments and Hedging Activities.~~.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The Company’s forward exchange contracts generally have maturities of one month or less and are closed out and rolled over into new contracts at the end of each monthly reporting period. Consequently, the fair value of these contracts has historically not been significant at the end of each reporting period.Typically, realized gains and losses on forward exchange contracts, which arise as a result of closing out the contracts at the end of each reporting period, are substantially offset by revaluation losses and gains on the underlying balances denominated in non-functional currencies. However, an inaccurate forecast of foreign currency assets or liabilities, coupled with a currency movement, would result in a gain or loss on a net basis. Gains and losses on forward exchange contracts and from revaluation of the underlying asset and liability balances denominated in non-functional currencies are recognized in the Unaudited Condensed Consolidated Statement of Earnings in selling, general and administrative expenses.

During the fiscal ~~quarter~~quarters ended January 1, 2010 and ~~six months ended April 3,~~January 2, 2009, ~~the Company recognized a net foreign currency gain of $0.2 million and a net foreign currency loss of $0.9 million, respectively. During the fiscal quarter and six months ended March 28, 2008,~~ the Company recognized net foreign currency gains of ~~$0.6~~$0.7 million and ~~$0.9~~losses of $1.1 million, respectively.

Other than foreign exchange forward contracts, the Company has no other freestanding or embedded derivative instruments, although the Company may use other derivative instruments in the future. The Company has not entered into forward exchange contracts for speculative or trading purposes.

As of ~~April 3, 2009,~~January 1, 2010, the Company had foreign exchange forward contracts to purchase the U.S. dollar equivalent of ~~$78.4~~$58.3 million and to sell the U.S. dollar equivalent of ~~$11.8~~$12.8 million in various foreign currencies.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

Effective October 3, 2009 (the first day of fiscal year 2010), the Company adopted revised accounting standards for business combinations. These revised standards generally require an entity to recognize the assets acquired, liabilities assumed, contingencies and contingent consideration at their fair value on the acquisition date. The adoption of the revised standards had no financial impact on the Company’s financial condition or results of operations. The new guidance is only applicable to acquisitions completed after the adoption date with the exception of certain tax contingencies and adjustments to valuation allowances, which previously were adjusted to goodwill but must now be adjusted to income tax expense regardless of the date of the original acquisition.

Contingent Consideration Arrangements. The Company is, from time to time, obligated to pay additional cash purchase price amounts in the event that certain financial or operational milestones are met by acquired businesses. As of ~~April 3, 2009,~~January 1, 2010, up to a maximum of ~~$10.3~~$10.1 million could be payable through April 2011 under contingent consideration arrangements relating to acquired businesses. Amounts subject to these arrangements can be earned over the respective measurement period, depending on the performance of the acquired business relative to certain financial and/or operational targets.

The following table summarizes ~~outstanding~~ contingent consideration arrangements as of ~~April 3, 2009:~~January 1, 2010:

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

During the first quarter of fiscal year 2010, the Company made a cash payment of $1.3 million which was accrued as part of the purchase price to secure the seller’s indemnification obligations in connection with the acquisition of the Analogix Business in fiscal year 2007.

Changes in the carrying amount of goodwill for each of the Company’s reporting segments in the first ~~six months~~quarter of fiscal year ~~2009~~2010 were as ~~follow:~~follows:

~~As required by SFAS 142,~~~~Goodwill and Other Intangible Assets~~, the Company performs an annual goodwill impairment assessment. This assessment is performed in the second quarter of each fiscal year. During the fiscal quarter ended April 3, 2009, the Company completed its annual impairment test and determined that there was no impairment of goodwill.

The following intangible assets have been recorded and are being amortized by the Company:


	April 3, 2009							January 1, 2010
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
(in thousands)
Intangible assets
Existing technology	$	14,855	$	(9,921	)	$	4,934	$	16,275	$	(12,292	)	$	3,983
Patents and core technology		36,589		(14,756	)		21,833		38,444		(18,379	)		20,065
Trade names and trademarks		2,378		(2,023	)		355		2,474		(2,156	)		318
Customer lists		12,288		(10,266	)		2,022		13,014		(11,339	)		1,675
Other		2,829		(2,462	)		367		3,196		(2,677	)		519

Total	$	68,939	$	(39,428	)	$	29,511	$	73,403	$	(46,843	)	$	26,560


								October 2, 2009
								Gross		Accumulated Amortization			Net
(in thousands)
Intangible assets
Existing technology								$	16,244	$	(11,738	)	$	4,506
Patents and core technology									38,515		(17,349	)		21,166
Trade names and trademarks									2,400		(2,120	)		280
Customer lists									12,996		(11,173	)		1,823
Other									3,227		(2,668	)		559

Total								$	73,382	$	(45,048	)	$	28,334

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Amortization expense relating to intangible assets was $1.8 million and ~~$3.9~~$2.1 million during the fiscal ~~quarter~~quarters ended January 1, 2010 and ~~six months ended April 3,~~January 2, 2009, respectively. ~~Amortization expense relating to intangible assets was $2.0 million and $3.8 million during the fiscal quarter and six months ended March 28, 2008, respectively. As of April 3, 2009,~~At January 1, 2010, estimated amortization expense for the remainder of fiscal year ~~2009~~2010 and for each of the five succeeding fiscal years and thereafter follows:


(in thousands)
Estimated amortization expense
Six months ending October 2, 2009	$	3,304
Fiscal year 2010		6,569
Nine months ending October 1, 2010			$	5,413
Fiscal year 2011		4,682		5,020
Fiscal year 2012		3,795		4,063
Fiscal year 2013		3,299		3,536
Fiscal year 2014		3,153		3,368
Fiscal year 2015				3,264
Thereafter		4,709		1,896

Total	$	29,511	$	26,560

Summary of Restructuring Plans.The Company has committed to several restructuring plans in order to improve operational efficiencies, centralize functions, reallocate resources and reduce operating costs.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

The following table sets forth changes in the Company’s aggregate restructuring liability relating to all ongoing restructuring plans during the first ~~and second quarters~~quarter of fiscal year ~~2009~~2010 as well as total restructuring expense and other related costs recorded since the inception of those plans:


	Employee- Related			Facilities- Related			Total				Employee- Related			Facilities- Related			Total
(in thousands)
Balance at October 3, 2008	$	1,840		$	982		$	2,822
Balance at October 2, 2009											$	579		$	398		$	977
Charges to expense, net		925			—			925				34			—			34
Cash payments		(601	)		(38	)		(639	)			(248	)		(10	)		(258	)
Foreign currency impacts and other adjustments		47			(56	)		(9	)			(2	)		(2	)		(4	)

Balance at January 2, 2009		2,211			888			3,099
Charges to (reversals of) expense, net		6,577			(317	)		6,260
Cash payments		(4,560	)		(182	)		(4,742	)
Foreign currency impacts and other adjustments		22			(40	)		(18	)

Balance at April 3, 2009	$	4,250		$	349		$	4,599
Balance at January 1, 2010											$	363		$	386		$	749


Total expense since inception of plans
														Restructuring Expense			Other Restructuring- related Costs (1)
(in millions)
Restructuring expense							$	13.4
Fiscal Year 2009 Second Quarter Plan										Fiscal Year 2009 Second Quarter Plan				$	6.1		$	1.1
Fiscal Year 2009 First Quarter Plan										Fiscal Year 2009 First Quarter Plan					1.4			0.1
Fiscal Year 2007 Plan										Fiscal Year 2007 Plan					2.9			8.7
Fiscal Year 2005 Plan										Fiscal Year 2005 Plan					1.8			0.7

Other restructuring-related costs⁽¹⁾							$	7.7
Total										Total				$	12.2		$	10.6

~~Fiscal Year 2009 Second Quarter Plan~~. During the second quarter of fiscal year 2009, the Company committed to a plan to reduce its cost structure, primarily through headcount reductions, due to continuing uncertainty in the global economic environment. The plan primarily involved the elimination of approximately 240 regular employee and 80 temporary positions (primarily in North America and Europe and, to a lesser extent, Asia Pacific and Latin America) in both the Scientific Instruments and Vacuum Technologies segments. In addition, the plan included the closure of one small R&D/manufacturing facility in North America (Lake Forest, California) and two sales offices in Europe (Sweden and Switzerland).

Restructuring and other related costs to be incurred in connection with this plan are currently estimated to be between $8.5 million and $10.5 million, of which between $8.0 million and $9.5 million is expected to impact the Scientific Instruments segment and between $0.5 million and $1.0 million is expected to impact the Vacuum Technologies segment. The restructuring costs include one-time termination benefits for employees whose positions are being eliminated of between $7.5 million and $9.0 million and lease termination costs of between $0.1 million and $0.2 million (including future lease payments on vacated facilities). Other restructuring-related costs include employee retention and relocation costs of between $0.3 million and $1.0 million and facility-related relocation costs and accelerated depreciation of fixed assets to be disposed upon the closure of facilities of between $0.1 million and $0.3 million. These costs are being recorded and included in cost of sales, selling, general and administrative expenses and research and development expenses.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

~~The following table sets forth changes in the Company’s restructuring liability relating to the foregoing plan during the second quarter of fiscal year 2009:~~

The restructuring expense of $6.4 million recorded during the second quarter of fiscal year 2009 related to employee termination benefits of which $5.7 million impacted the Scientific Instruments segment and $0.7 million impacted the Vacuum Technologies segment. The Company also incurred $0.3 million in other restructuring-related costs during the quarter, which impacted the Scientific Instruments segment and were comprised of $0.1 million in employee-related costs and a $0.2 million non-cash charge for accelerated depreciation of assets to be disposed upon the closure of facilities. Most of these costs are expected to be settled during fiscal year 2009, although certain one-time termination benefits are expected to be settled in fiscal year 2010.

~~Fiscal Year 2009 First Quarter Plan.~~ During the first quarter of fiscal year 2009, the Company committed to a separate plan to reduce its employee headcount in order to reduce operating costs and increase margins. The plan involves the termination of approximately 35 employees, mostly located in Europe. The restructuring costs related to this plan primarily consist of one-time termination benefits. This restructuring plan did not involve any non-cash components. Costs relating to restructuring activities recorded under this plan have been included in cost of sales, selling, general and administrative expenses and research and development expenses.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~The following table sets forth changes in the Company’s restructuring liability relating to the foregoing plan during the first and second quarters of fiscal year 2009:~~

The restructuring expense of $1.3 million recorded during the first six months of fiscal year 2009 related to employee termination benefits, of which $1.2 million impacted the Scientific Instruments segment and $0.1 million impacted the Vacuum Technologies segment.

~~Fiscal Year 2007 Plan~~. During fiscal year 2007, the Company committed to a plan to combine and optimize the development and assembly of most of its nuclear magnetic resonance (“NMR”) and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies. As part of the plan, the Company is creating an information rich detection (“IRD”) center in Walnut Creek, California, where NMR operations are being integrated with mass spectrometry operations already located in Walnut Creek. The Company is investing in a new 45,000 square foot building and a substantial remodel of an existing building there to house the IRD center.

As a result of the plan, a number of employee positions have been or will be relocated or eliminated and certain facilities will be consolidated. These actions primarily impact the Scientific Instruments segment and involve the elimination of between approximately 40 and 60 positions.

Restructuring and other related costs associated with this plan include one-time termination benefits, retention payments, costs to relocate facilities (including decommissioning costs, moving costs and temporary facility/storage costs), accelerated depreciation of fixed assets to be disposed as a result of facilities actions and lease termination costs. Costs relating to restructuring activities recorded under this plan have been included in cost of sales, selling, general and administrative expenses and research and development expenses.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~The following table sets forth changes in the Company’s restructuring liability relating to the foregoing plan during the first and second quarters of fiscal year 2009:~~

The net reversals of restructuring expense of $0.1 million and $0.5 million recorded during the fiscal quarter and six months ended April 3, 2009, respectively, related to changes in estimates of certain employee termination benefits and the early cancellation of a lease agreement for a vacated facility. The Company also incurred $0.5 million and $1.2 million in other restructuring-related costs during the fiscal quarter and six months ended April 3, 2009, respectively. These costs were related to employee retention costs and facilities-related costs including decommissioning costs and non-cash charges for accelerated depreciation of assets to be disposed upon the closure of facilities.

Product Warranties. The Company’s products are generally subject to warranties. Liabilities for the estimated future costs of repair or replacement are established and charged to cost of sales at the time the related sale is recognized. The amount of liability to be recorded is based on management’s best estimates of future warranty costs after considering historical and projected product failure rates and product repair costs.

Changes in the Company’s estimated liability for product warranty during the ~~six months~~fiscal quarters ended ~~April 3,~~January 1, 2010 and January 2, 2009 ~~and March 28, 2008~~ follow:

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

Indemnification Obligations. ~~Financial Accounting Standards Board (“FASB”) Interpretation No. (“FIN”) 45,~~ASC 460,~~Guarantor’s Accounting and Disclosure Requirements for~~ Guarantees ~~Including Indirect Guarantees of Indebtedness of Others~~, requires a guarantor to recognize a liability for and/or disclose obligations it has undertaken in relation to the issuance of the guarantee. Under this guidance, arrangements involving indemnification clauses are subject to the disclosure requirements of ~~FIN 45~~ASC 460 only.

The Company is subject to certain indemnification obligations to VMS (formerly VAI) and VSEA in connection with the Instruments business as conducted by VAI prior to the Distribution (described in Note 2). These indemnification obligations cover a variety of aspects of the Company’s business, including, but not limited to, employee, tax, intellectual property, litigation and environmental matters. Certain of the agreements containing these indemnification obligations are disclosed as exhibits to the Company’s Annual Report on Form 10-K. The estimated fair value of these indemnification obligations is not considered to be material.

The Company is subject to certain indemnification obligations to Jabil Circuit, Inc. (“Jabil”) in connection with the Company’s sale of its Electronics Manufacturing Business to Jabil. These indemnification obligations cover certain aspects of the Company’s conduct of the Electronics Manufacturing Business prior to its sale to Jabil, including, but not limited to, employee, tax, litigation and environmental matters. The agreement containing these indemnification obligations is disclosed as an exhibit to the Company’s Annual Report on Form 10-K. The estimated fair value of these indemnification obligations is not considered to be material.

The Company’s By-Laws require it to indemnify its officers and directors, as well as those who act as directors and officers of other entities at the request of the Company, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to the Company. In addition, the Company has entered into separate indemnity agreements with each director and officer that provide for indemnification of these directors and officers under certain circumstances. The form of these indemnity agreements is disclosed as an exhibit to the Company’s Annual Report on Form 10-K. The indemnification obligations are more fully described in these indemnity agreements and the Company’s By-Laws. The Company purchases insurance to cover claims or a portion of any claims made against its directors and officers. Since a maximum obligation is not explicitly stated in the Company’s By-Laws or these indemnity agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot reasonably be estimated. Historically, the Company has

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

not made payments related to these indemnification obligations and the estimated fair value of these indemnification obligations is not considered to be material.

As is customary in the Company’s industry and as provided for in local law in the U.S. and other jurisdictions, many of the Company’s standard contracts provide remedies to customers and other third parties with whom the Company enters into contracts, such as defense, settlement or payment of judgment for intellectual property claims related to the use of its products. From time to time, the Company also agrees to indemnify customers, suppliers, contractors, lessors, lessees and others with whom it enters into contracts, against loss, expense and/or liability arising from various triggering events related to the sale and the use of the Company’s products and services, the use of their goods and services, the use of facilities and other matters covered by such contracts, usually up to a specified maximum amount. In addition, from time to time, the Company sometimes also agrees to indemnify these parties against claims related to undiscovered liabilities, additional product liability or environmental obligations. Claims made under such indemnification obligations have been insignificant and the estimated fair value of these indemnification obligations is not considered to be material.

Credit Facilities. The Company maintains relationships with banks in many countries from whom it sometimes obtains bank guarantees and short-term standby letters of credit. These guarantees and letters of credit

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

relate primarily to advance payments and deposits made to the Company’s subsidiaries by customers for which separate liabilities are recorded in the unaudited condensed consolidated financial statements. As of ~~April 3, 2009,~~January 1, 2010, a total of ~~$18.1~~$13.8 million of these bank guarantees and letters of credit were outstanding. No amounts had been drawn by beneficiaries under these or any other outstanding guarantees or letters of credit as of that date.

Long-term Debt. As of both ~~April 3, 2009~~January 1, 2010 and October ~~3, 2008,~~2, 2009, the Company had an $18.8 million term loan outstanding with a U.S. financial institution at a fixed interest rate of 6.7%. The term loan contains certain covenants that limit future borrowings and the payment of cash dividends and require the maintenance of certain levels of working capital and operating results. The Company was in compliance with all restrictive covenants of the term loan agreement at ~~April 3, 2009.~~January 1, 2010.

The following table summarizes future principal payments on borrowings under long-term debt outstanding as of ~~April 3, 2009:~~January 1, 2010:


	Six Months Ending Oct. 2, 2009			Fiscal Years																				Nine Months Ending Oct. 1, 2010			Fiscal Years
			2010			2011			2012			2013			2014			Thereafter			Total					2011			2012			2013			2014			2015			Thereafter			Total
(in thousands)
Long-term debt	$	—		$	6,250		$	—		$	6,250		$	—		$	6,250		$	—		$	18,750
(including current portion)																								$	6,250		$	—		$	6,250		$	—		$	6,250		$	—		$	—		$	18,750

Based upon rates currently available to the Company for debt with similar terms and remaining maturities, the carrying amount of long-term debt approximates the estimated fair value.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Net Periodic Pension Cost. The components of net periodic pension cost relating to the Company’s defined benefit retirement plans follow:


													Fiscal Quarter Ended
	Fiscal Quarter Ended						Six Months Ended						January 1,			January 2,
	April 3, 2009			March 28, 2008			April 3, 2009			March 28, 2008			2010			2009
(in thousands)
Service cost	$	249		$	343		$	498		$	686		$	133		$	249
Interest cost		705			723			1,410			1,446			679			705
Expected return on plan assets		(570	)		(653	)		(1,140	)		(1,306	)		(511	)		(570	)
Amortization of prior service cost and actuarial gains and losses		17			—			34			—			(1	)		17
Curtailment loss recognized		135			—			135			—

Net periodic pension cost	$	536		$	413		$	937		$	826		$	300		$	401

Employer Contributions. During the fiscal quarter ~~and six months~~ ended ~~April 3, 2009,~~January 1, 2010, the Company made contributions totaling ~~$0.3 million and $0.6~~approximately $0.1 million to its defined benefit pension plans. The Company currently anticipates contributing an additional ~~$0.1~~$0.2 million to these plans in the remaining ~~six~~nine months of fiscal year ~~2009.~~

~~Defined Benefit Pension Plan Curtailment~~. During the second quarter of fiscal year 2009, the Company ceased future benefit accruals to a defined benefit pension plan in the United Kingdom. In connection with this action, the Company recorded a curtailment loss of $0.1 million during the second quarter of fiscal year 2009.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~2010.

Environmental Matters. The Company’s operations are subject to various federal, state and local laws in the U.S. as well as laws in other countries regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. These regulations increase the costs and potential liabilities of the Company’s operations. However, the Company does not currently anticipate that its compliance with these regulations will have a material effect on the Company’s capital expenditures, earnings or competitive position.

The Company and VSEA are each obligated (under the terms of the Distribution described in Note 2) to indemnify VMS for one-third of certain costs (after adjusting for any insurance recoveries and tax benefits recognized or realized by VMS for such costs) relating to (a) environmental investigation, monitoring and/or remediation activities at certain facilities previously operated by VAI and third-party claims made in connection with environmental conditions at those facilities, and (b) U.S. Environmental Protection Agency or third-party claims alleging that VAI or VMS is a potentially responsible party under the Comprehensive Environmental Response Compensation and Liability Act of 1980, as amended (“CERCLA”) in connection with certain sites to which VAI allegedly shipped manufacturing waste for recycling, treatment or disposal (the “CERCLA sites”). With respect to the facilities formerly operated by VAI, VMS is overseeing the environmental investigation, monitoring and/or remediation activities, in most cases under the direction of or in consultation with federal, state and/or local agencies, and handling third-party claims. VMS is also handling claims relating to the CERCLA sites. ~~The Company is also undertaking environmental investigation and/or monitoring activities at one of its facilities under the direction of or in consultation with governmental agencies.~~

Various uncertainties make it difficult to estimate future costs for certain of these environmental-related activities, specifically external legal expenses, VMS’ internal oversight costs, third-party claims and a former VAI facility where the likelihood and scope of further environmental-related activities are difficult to assess. As of ~~April 3, 2009,~~January 1, 2010, it was nonetheless estimated that the Company’s future exposure for these environmental-related costs ranged in the aggregate from ~~$1.1~~$1.0 million to $2.5 million. The time frame over which these costs are expected to be incurred varies with each type of cost, ranging up to approximately 30 years as of ~~April 3, 2009.~~January 1, 2010. No amount in the foregoing range of estimated future costs is discounted, and no amount in the range is believed to be more probable of being incurred than any other amount in such range. The Company therefore had an accrual of ~~$1.1~~$1.0 million as of ~~April 3, 2009,~~January 1, 2010 for these future environmental-related costs.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Sufficient knowledge has been gained to be able to better estimate other costs for future environmental-related activities. As of ~~April 3, 2009,~~January 1, 2010, it was estimated that the Company’s future costs for these environmental-related activities ranged in the aggregate from ~~$2.2~~$2.5 million to ~~$13.0~~$12.7 million. The time frame over which these costs are expected to be incurred varies, ranging up to approximately 30 years as of ~~April 3, 2009.~~January 1, 2010. As to each of these ranges of cost estimates, it was determined that a particular amount within the range was a better estimate than any other amount within the range. Together, these amounts totaled ~~$5.7~~$5.5 million at ~~April 3, 2009.~~January 1, 2010. Because both the amount and timing of the recurring portion of these costs were reliably determinable, that portion is discounted at 4%, net of inflation. The Company therefore had an accrual of $4.0 million as of ~~April 3, 2009,~~January 1, 2010, which represents its best estimate of these future environmental-related costs after discounting estimated recurring future costs. This accrual is in addition to the ~~$1.1~~$1.0 million described in the preceding paragraph.

The Company has not reduced any environmental-related liability in anticipation of recoveries from third parties. However, an insurance company has agreed to pay a portion of certain of VAI’s (now VMS’) future environmental-related costs, for which the Company has an indemnification obligation, and the Company therefore has a long-term receivable of $1.0 million (discounted at 4%, net of inflation) in Other assets as of ~~April 3, 2009,~~January 1, 2010, for the Company’s share of that insurance recovery.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

The Company believes that its reserves for the foregoing and other environmental-related matters are adequate, but as the scope of its obligation becomes more clearly defined, these reserves may be modified and related charges against or credits to earnings may be made. Although any ultimate liability arising from environmental-related matters could result in significant expenditures that, if aggregated and assumed to occur within a single fiscal year, would be material to the Company’s financial statements, the likelihood of such occurrence is considered remote. Based on information currently available and its best assessment of the ultimate amount and timing of environmental-related events, the Company believes that the costs of ~~environmental-related~~environmental- related matters are not reasonably likely to have a material adverse effect on the Company’s financial condition or results of operations.

Legal Proceedings. The Company is involved in pending legal proceedings that are ordinary, routine and incidental to its business. While the ultimate outcome of these legal matters is not determinable, the Company believes that these matters are not reasonably likely to have a material adverse effect on the Company’s financial condition or results of operations.

~~Stock Rights.~~ On April 2, 1999, stockholders of record of VAI on March 24, 1999 received in the Distribution (described in Note 2) one share of the Company’s common stock for each share of VAI common stock held on April 2, 1999. Each stockholder also received one preferred stock purchase right (“Right”) for each share of common stock distributed, entitling the stockholder to purchase one one-thousandth of a share of Participating Preferred Stock, par value $0.01 per share, for $200.00 (subject to adjustment), in the event of certain changes in the Company’s ownership. The Participating Preferred Stock was designed so that each one one-thousandth of a share had economic and voting terms similar to those of one share of common stock. During the second quarter of fiscal year 2009, the Rights expired. As of April 2, 2009, when the Rights had expired, no Rights were eligible to be exercised and none had been exercised through that date.

Share-Based Compensation Expense. The following table summarizes the amount of share-based compensation expense by award type as well as the effect of this expense on income tax expense and net earnings:

Share-based compensation expense included in the preceding table related to restricted (non-vested) stock includes $49,000 and $154,000 in the fiscal quarter and six months ended April 3, 2009, respectively, related to restricted stock granted in connection with the Company’s fiscal year 2007 restructuring plan.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Share-based compensation expense in the preceding table related to restricted (nonvested) stock includes $35,000 in the fiscal quarter ended January 1, 2010 and $104,000 in the fiscal quarter ended January 2, 2009, related to restricted stock granted in connection with the Company’s fiscal year 2007 restructuring plan.

Share-based compensation expense has been included in the Company’s ~~Unaudited Condensed Consolidated Statement~~unaudited condensed consolidated statement of ~~Earnings~~earnings as follows:


	Fiscal Quarter Ended				Six Months Ended				Fiscal Quarter Ended
	April 3, 2009		March 28, 2008		April 3, 2009		March 28, 2008		January 1, 2010		January 2, 2009
(in thousands)
Cost of sales	$	87	$	108	$	220	$	232	$	63	$	133
Selling, general and administrative		1,834		2,878		3,953		4,339		1,108		2,119
Research and development		24		117		138		251		61		114

Total	$	1,945	$	3,103	$	4,311	$	4,822	$	1,232	$	2,366

Stock Options.Under the Omnibus Stock Plan (“OSP”), the Company periodically grants stock options to officers, directors and employees. The exercise price for stock options granted under the OSP may not be less than 100% of the fair market value at the date of the grant. Options granted are exercisable at the times and on the terms established by the Compensation Committee, but not later than ten years after the date of grant (except in the event of death, after which an option is exercisable for three years). ~~Stock~~Options granted generally become exercisable in cumulative installments of one-third each year commencing one year following the date of grant. In accordance with covenants of the Merger Agreement, the Company did not grant any stock options ~~generally vest in three equal annual installments over three years from~~under the ~~grant date.~~OSP during the first quarter of fiscal year 2010.

The following table summarizes stock option activity under the OSP for the ~~six months~~fiscal quarter ended ~~April 3, 2009:~~January 1, 2010:

As of ~~April 3, 2009,~~January 1, 2010, the unrecognized share-based compensation balance related to stock options was ~~$5.4~~$2.4 million. This amount will be recognized as expense using the straight-line attribution method over a weighted-average amortization period of ~~1.3~~1.2 years.

Restricted (Nonvested) Stock.Under the OSP, the Company also periodically grants restricted (nonvested) common stock to employees. Such grants are valued as of the grant date. These amounts are recognized by the Company as share-based compensation expense ratably over their respective vesting periods, which range from one to three years. In accordance with covenants of the Merger Agreement, the Company did not grant any restricted (nonvested) common stock under the OSP during the first quarter of fiscal year 2010.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The following table summarizes restricted (nonvested) common stock activity under the OSP for the ~~six months~~fiscal quarter ended ~~April 3, 2009:~~January 1, 2010:

As of ~~April 3, 2009,~~January 1, 2010, there was a total of ~~$2.3~~$2.4 million in unrecognized share-based compensation expense related to restricted stock granted under the OSP. This expense will be recognized over a weighted-average amortization period of ~~2.4~~1.9 years.

~~Non-Employee Director Stock Units~~. Under the terms of the OSP, on the first business day following each annual meeting of the Company’s stockholders, each person then serving as a non-employee director is automatically granted stock units having an initial value of $45,000. The stock units will vest upon termination of the director’s service on the Board of Directors and will then be satisfied by issuance of shares of the Company’s common stock. Each non-employee director who holds stock units will not have rights as a stockholder with respect to the shares issuable thereunder until such shares are paid out. The stock units are not transferable, except to the non-employee director’s designated beneficiary or estate in the event of his or her death. During the fiscal quarters ended April 3, 2009 and March 28, 2008, the Company granted stock units with an aggregate value of $225,000 to non-employee members of its Board of Directors (of which there were five) and recognized the total value as share-based compensation expense at the time of grant in each of those respective periods.

Employee Stock Purchase Plan.During the fiscal quarter ~~and six months~~ ended ~~April 3, 2009,~~January 1, 2010, employees purchased approximately ~~42,000~~21,100 shares for ~~$1.2~~$0.7 million ~~and 69,000 shares for $2.1 million, respectively,~~ under the Company’s Employee Stock Purchase Plan (“ESPP”). During the fiscal quarter ~~and six months~~ ended ~~March 28, 2008,~~January 2, 2009, employees purchased approximately ~~21,000~~27,100 shares for ~~$1.2~~$0.9 million ~~and 41,000 shares for $2.1 million, respectively,~~ under the ESPP. AsOn the first day of ~~April 3, 2009, a total of approximately 120,000 shares remained available for issuance~~fiscal year 2010, the Company suspended future purchases under the ~~ESPP.~~ESPP in accordance with covenants of the Merger Agreement.

Stock Repurchase Programs. In February 2008, the Company’s Board of Directors approved a stock repurchase program under which the Company is authorized to utilize up to $100 million to repurchase shares of its common stock. ~~This repurchase program is effective through December 31, 2009.~~ During the fiscal quarter ~~and six months~~ ended ~~April 3, 2009,~~January 1, 2010, the Company ~~repurchased and retired 344,100~~did not repurchase any shares of its common stock under this ~~authorization at an aggregate cost of $7.1 million. As of April 3, 2009, the Company had remaining authorization to~~authorization. This repurchase ~~$37.5 million of its common stock under this program.~~program expired on December 31, 2009.

Other Stock Repurchases.During the ~~six months~~fiscal quarter ended ~~April 3, 2009~~January 1, 2010, the Company repurchased and retired ~~11,000~~4,000 shares tendered to it by employees in settlement of employee tax withholding obligations due from those employees upon the vesting of restricted stock.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

~~The Company has equity investments in privately held companies which, because of its ownership interest and other factors, are carried at cost. The Company monitors these investments for impairment.~~

During the second quarter of fiscal year 2008, the Company became aware of information which raised substantial doubt about the ability of a small, privately held company in which the Company held a cost method equity investment to continue as a going concern. Based on this information, the Company determined that the fair value of its investment had declined and that the decline was other-than-temporary. As a result, the Company wrote off the entire $3.0 million carrying value of its investment via an impairment charge in that period.

The Company’s U.S. federal, state and local and foreign income tax returns are subject to audit by relevant tax authorities. Although the timing and outcome of income tax audits is highly uncertain, the Company has ~~reasonably~~ recorded liabilities for associated unrecognized tax benefits. It is possible that certain unrecognized tax benefits could decrease by ~~$1.1~~$0.8 million in the next twelve months due to the lapse of certain statutes of limitation and result in a reduction in income tax expense. Any such reduction could be impacted by other changes in unrecognized tax benefits.

Basic earnings per share are calculated based on net earnings and the weighted-average number of shares of common stock outstanding during the reported period. Diluted earnings per share are calculated similarly, except that the weighted-average number of common shares outstanding during the period is increased by the number of

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

additional shares of common stock that would have been outstanding if the dilutive potential shares of common stock had been issued. The dilutive effect of potential common stock (including outstanding stock options, ~~unvested~~nonvested restricted stock and non-employee director stock units) is reflected in diluted earnings per share by application of the treasury stock method, which includes consideration of share-based compensation and the tax benefit ~~thereon as required by SFAS 123(R).~~thereon.

For the fiscal ~~quarter~~quarters ended January 1, 2010 and ~~six months ended April 3,~~January 2, 2009, options to purchase ~~1,875,000~~293,000 and 1,828,000 shares, respectively, were excluded from the calculation of diluted earnings per share as their effect was anti-dilutive. For the fiscal quarter and six months ended March 28, 2008, options to purchase 265,000 and 256,0001,790,000 shares, respectively, were excluded from the calculation of diluted earnings per share as their effect was anti-dilutive.

A reconciliation of weighted-average basic shares outstanding to weighted-average diluted shares outstanding follows:


	Fiscal Quarter Ended		Six Months Ended		Fiscal Quarter Ended
	April 3, 2009	March 28, 2008	April 3, 2009	March 28, 2008	January 1, 2010	January 2, 2009
(in thousands)
Weighted-average basic shares outstanding	28,853	29,830	28,853	30,080	28,863	28,854
Net effect of dilutive potential common stock	99	413	110	518	383	96

Weighted-average diluted shares outstanding	28,952	30,243	28,963	30,598	29,246	28,950

~~VARIAN, INC. AND SUBSIDIARY COMPANIES~~During the first quarter of fiscal year 2010, the Company adopted ASC 260-10-45 to 65,Earnings per Share, which addresses whether nonvested instruments granted in share-based payment transactions that contain non-forfeitable rights to dividends or dividend equivalents are participating securities subject to the two-class method of computing earnings per share. Although our nonvested restricted stock awards are considered participating securities, they are not material as compared with total weighted average diluted shares outstanding and are therefore not presented using the two-class method.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

For financial reporting purposes, the Company’s operations are grouped into two business segments: Scientific Instruments and Vacuum Technologies. The Scientific Instruments segment designs, develops, manufactures, markets, sells and services equipment and related software, consumable products, accessories and services for a broad range of life science, environmental, energy, and applied research and other applications requiring identification, quantification and analysis of the composition or structure of liquids, solids or gases. The Vacuum Technologies segment designs, develops, manufactures, markets, sells and services vacuum products and related accessories and services used to create, contain, control, measure and test vacuum environments in a broad range of life science, industrial and other applications requiring ultra-clean or high-vacuum environments. These segments were determined in accordance with ~~SFAS 131,~~ASC 280,~~Disclosures about Segments of an Enterprise and Related Information~~Segment Reporting.

General corporate costs include shared costs of legal, tax, accounting, treasury, insurance and certain other management costs. A portion of the indirect and common costs has been allocated to the segments through the use of estimates. Also, transactions between segments are accounted for at cost and are not included in sales. Accordingly, the following information is provided for purposes of achieving an understanding of operations, but might not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies might not be meaningful.

~~In September 2006, the FASB issued SFAS 157,~~ ~~Fair Value Measurements,~~ ~~which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. In~~

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

~~February 2008, the FASB issued FASB Staff Position (“FSP”) 157-2,~~~~Effective Date of FASB Statement No. 157,~~which delays the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities to fiscal years beginning after November 15, 2008, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). The Company adopted SFAS 157 effective October 4, 2008 with the exception of the application of the statement to nonrecurring nonfinancial assets and nonfinancial liabilities (see Note 4). The Company does not expect the adoption of the provisions deferred by FSP 157-2 to have a material impact on its financial condition or results of operations.

~~In December 2007, the FASB issued SFAS 141 (revised 2007),~~~~Business Combinations~~, (“SFAS 141(R)”). SFAS 141(R) retains the fundamental requirements of the original pronouncement requiring that the purchase method be used for all business combinations but also provides revised guidance for recognizing and measuring identifiable assets and goodwill acquired, liabilities assumed, and any noncontrolling interest in the acquiree. It also requires the recognition of assets acquired and liabilities assumed arising from contingencies, the capitalization of in-process research and development at fair value, and the expensing of acquisition-related costs as incurred.SFAS 141(R) also requires that certain tax contingencies and adjustments to valuation allowances related to business combinations, which previously were adjusted to goodwill, must be adjusted to income tax expense, regardless of the date of the original business combination. SFAS 141(R) is effective for fiscal years beginning after December 15, 2008. The Company does not expect its adoption in the first quarter of fiscal year 2010 to have a material impact on the Company’s financial condition or results of operations. However, in the event that the Company completes acquisitions subsequent to its adoption of SFAS 141(R), the application of its provisions will likely have a material impact on the Company’s results of operations, although the Company is not currently able to estimate that impact.

~~In April 2009, the FASB issued FSP FAS 141(R)-1,~~~~Accounting for Assets Acquired and Liabilities Assumed in a Business Combination That Arise from Contingencies~~, which amends the accounting prescribed in SFAS 141(R) for assets and liabilities arising from contingencies in business combinations. FSP FAS 141(R)-1 requires pre-acquisition contingencies to be recognized at fair value if fair value can be reasonably determined during the measurement period. If fair value cannot be reasonably determined, the FSP requires measurement based on the recognition and measurement criteria of SFAS 5,~~Accounting for Contingencies.~~~~The adoption of FSP FAS 141(R)-1 could have a material impact on the Company’s results of operations, although the Company is not currently able to estimate that impact.~~

~~In December 2007, the FASB issued SFAS 160,~~~~Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51~~. SFAS 160 requires that ownership interests in subsidiaries held by parties other than the parent and the amount of consolidated net income be clearly identified, labeled and presented in the consolidated financial statements. It also requires once a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary be initially measured at fair value. Sufficient disclosures are required to clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS 160 is effective for fiscal years beginning after December 15, 2008, and requires retroactive adoption of the presentation and disclosure requirements for existing minority interests. All other requirements are applied prospectively. The Company does not expect the adoption of SFAS 160 to have a material impact on its financial condition or results of operations.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

December 15, 2008, and must be applied prospectively to intangible assets acquired after the effective date. Early adoption is prohibited. Given that FSP 142-3 applies to intangible assets acquired after the effective date, the Company does not expect its adoption to have a material impact on its financial condition or results of operations.

~~In June 2008, the FASB issued FSP EITF 03-6-1,~~~~Determining~~~~Whether Instruments Granted in Share-Based Payment Transactions are Participating Securities~~. FSP EITF 03-6-1 states that unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents are participating securities and shall be included in the computation of earnings per share under the two-class method described in SFAS 128,~~Earnings per Share~~. FSP EITF 03-6-1 is effective for fiscal years beginning after December 15, 2008, and interim periods within those years, on a retrospective basis. The Company does not expect the adoption of FSP EITF 03-6-1 to have a material impact on its earnings per share.

In December 2008, the FASB issued ~~FSP 132(R)-1,~~~~Employers’ Disclosures about Postretirement Benefit Plan Assets~~~~. FSP 132(R)-1 amends SFAS 132 (revised 2003),~~~~Employers’ Disclosures about Pensions and Other Postretirement Benefits~~~~, to provide guidance on an employer’s disclosures about~~additional disclosure requirements for plan assets of a defined benefit pension or other postretirement plan. ~~This FSP is~~The required disclosures include a description of the Company’s investment policies and strategies, the fair value of each major category of plan assets, the inputs and valuation techniques used to measure the fair value of plan assets, the effect of fair value measurements using significant unobservable inputs on changes in plan assets and the significant concentrations of risk within plan assets. These additional disclosures are effective for annual disclosure for fiscal years ending after December 15, 2009. The Company does not expect the adoption of ~~FSP 132(R)-1~~the new disclosure requirements to have a material impact on its financial condition or results of operations.

In October 2009, the FASB issued two new accounting standards that provide guidance for revenue recognition. The first standard revises guidance for arrangements with multiple deliverables. This accounting standard replaces the term fair value in the revenue recognition allocation guidance with selling price and establishes a hierarchy for determining the selling price of a deliverable. The selling price of each deliverable will first be based on vendor specific objective evidence (“VSOE”) if available, second on third-party evidence (“TPE’) if VSOE is not available and third on estimated selling price if neither VSOE nor TPE is available. In addition, the residual method is no longer permitted as vendors are now required to allocate arrangement consideration using the relative selling price method. The second new accounting standard excludes from the scope of software revenue recognition software components contained in, and essential to the functionality of, tangible products. These two new accounting standards require expanded qualitative and quantitative disclosures and are effective for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. Early adoption is permitted. The Company does not expect the adoption of these accounting standards in the first quarter of fiscal year 2011 to have a material impact on its financial condition or results of operations.

In January 2010, the FASB issued an accounting standard update that clarifies and provides additional disclosure requirements related to recurring and non-recurring fair value measurements and employers’ disclosures about postretirement benefit plan assets. These additional disclosures are effective for interim and annual reporting periods beginning after December 15, 2009. The Company does not expect the adoption of this accounting standard update in the second quarter of fiscal year 2010 to have a material impact on its financial condition or results of operations.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Throughout this Report, and particularly in thisItem 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations, there are forward-looking statements that are based upon our current expectations, estimates and projections and that reflect our beliefs and assumptions based upon information available to us at the date of this Report. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and other similar terms. These forward-looking statements include (but are not limited to) those relating to the timing and amount of anticipated restructuring and other related costs and related cost savings as well as anticipated ~~orders, revenues, earnings and~~ capital expenditures in fiscal year ~~2009.~~2010.

We caution investors that forward-looking statements are only our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements. Some of the important factors that could cause our results to differ are discussed inItem 1A—Risk Factors in our Annual Report on Form 10-K for the fiscal year ended October ~~3, 2008.~~2, 2009. We encourage you to read that section carefully.

Other risks and uncertainties that could cause actual results to differ materially from those in our forward-looking statements include, but are not limited to, the following: ~~when~~the pace and ~~how quickly~~extent of improvements in global economic ~~conditions improve, and whether conditions worsen before they improve,~~conditions; whether we will succeed in new product development, release, commercialization, performance and acceptance; whether we can achieve growth in sales for life science, environmental, energy ~~and/~~or applied research and other applications; whether we can achieve sales growth in Europe, North America, Asia Pacific ~~and/~~or Latin America; risks arising from the timing of shipments, installations and the recognition of revenues on certain research products, including nuclear magnetic resonance (“NMR”) spectroscopy systems, magnetic resonance (“MR”) imaging systems and fourier transform mass spectrometry (“FTMS”) systems and superconducting magnets; the impact of shifting product mix on profit margins; competitive products and pricing; economic conditions in our various product and geographic markets; whether we will see continued and timely delivery of key raw materials and components by suppliers; foreign currency fluctuations that could adversely impact revenue growth ~~and/~~or earnings; whether we will see continued investment in capital equipment, in particular given the global liquidity and credit ~~crisis; whether we will see reduced~~conditions; demand from customers that operate in cyclical industries; ~~whether~~ the extent to which global liquidity and credit ~~crisis will~~conditions impact the collectability of accounts receivable from our customers; the extent and timing of government funding for research; ~~our ability to successfully evaluate, negotiate, complete and integrate acquisitions, in particular given the greater difficulty to borrow in the current credit environment;~~ the actual costs, timing and benefits of restructuring activities (such as ~~the~~our previously announced employee reductions, ~~and other actions announced on January 16, 2009 and~~ our Northern California operations ~~consolidation)~~consolidation and other actions) and other efficiency improvement activities (such as our global procurement, lower-cost manufacturing and outsourcing initiatives); ~~variability in our effective income tax rate (due to factors including the timing and amount of discrete tax events and changes to unrecognized tax benefits);~~ the timing and amount of share-based compensation; the ability of our company and Agilent Technologies, Inc. (“Agilent”) to complete the announced acquisition of our company by Agilent (the “Merger”); the affect on our business operations and financial results of the announcement, the pendency, and activities relating to the completion of the Merger, including the recently announced undertaking to divest certain of the Company’s product lines in order to secure regulatory approval to complete the Merger; the affect of certain restrictions on our ability to conduct our business under the Merger agreement with Agilent; and other risks detailed from time to time in our filings with the U.S. Securities and Exchange Commission (the “SEC”). We undertake no special obligation to update any forward-looking statements, whether in response to new information, future events or otherwise.

~~Second~~First Quarter of Fiscal Year ~~2009~~2010 Compared to ~~Second~~First Quarter of Fiscal Year ~~2008~~2009

For financial reporting purposes, our operations are grouped into two reportable business segments: Scientific Instruments and Vacuum Technologies. The following table presents comparisons of our sales and operating earnings for each of those segments and in total for the ~~second quarters~~first quarter of fiscal years ~~2009~~2010 and ~~2008:~~2009:


	Fiscal Quarter Ended										Increase (Decrease)					Fiscal Quarter Ended										Increase (Decrease)
	April 3, 2009					March 28, 2008					Increase (Decrease)					January 1, 2010					January 2, 2009					Increase (Decrease)
	$			% of Sales		$			% of Sales		$			%		$			% of Sales		$			% of Sales		$			%
(dollars in millions)
Sales by Segment:
Scientific Instruments	$	170.9		83.2	%	$	204.4		82.4	%	$	(33.5	)	(16.4	)%	$	166.6		82.8	%	$	171.8		82.5	%	$	(5.2	)	(3.0	)%
Vacuum Technologies		34.5		16.8			43.8		17.6			(9.3	)	(21.0	)		34.6		17.2			36.4		17.5			(1.8	)	(5.0	)

Total company	$	205.4		100.0	%	$	248.2		100.0	%	$	(42.8	)	(17.2	)%	$	201.2		100.0	%	$	208.2		100.0	%	$	(7.0	)	(3.4	)%


Operating Earnings by Segment:
Scientific Instruments	$	12.4		7.3	%	$	22.5		11.0	%	$	(10.1	)	(44.8	)%	$	9.4		5.7	%	$	16.4		9.6	%	$	(7.0	)	(42.6	)%
Vacuum Technologies		6.7		19.2			8.8		20.1			(2.1	)	(24.3	)		7.1		20.6			7.1		19.3			—		—

Total segments		19.1		9.3			31.3		12.6			(12.2	)	(39.0	)		16.5		8.2			23.5		11.3			(7.0	)	(29.5	)
General corporate		(3.6	)	(1.7	)		(4.2	)	(1.7	)		0.6		15.1			(4.0	)	(2.0	)		(3.6	)	(1.7	)		(0.4	)	(14.5	)

Total company	$	15.5		7.5	%	$	27.1		10.9	%	$	(11.6	)	(42.8	)%	$	12.5		6.2	%	$	19.9		9.6	%	$	(7.4	)	(37.4	)%

Scientific Instruments. The decrease in Scientific Instruments sales was primarily attributable to lower sales volume and lower average selling prices of ~~our~~certain analytical instruments products partly offset by increased sales volume of our research products and consumables products. The weaker U.S. dollar had a positive impact on reported revenues. Revenue in the first quarter of fiscal year 2010 was affected by the negative impact of ~~the stronger U.S. dollar on reported revenues. The lower volume was primarily due~~customers’ uncertainty and employee and other disruptions related to the announcement and pendency of the acquisition by Agilent (particularly for analytical instruments products) and by the impact of ~~the~~ continued global economic weakness on capital equipment spending. ~~Sales from businesses acquired~~The increase in ~~fiscal~~research products revenue was primarily due to unusually low sales of these products in the prior year ~~2008 positively impacted reported sales~~quarter caused primarily by ~~approximately 1%.~~delays related to laboratory readiness and access to customer sites, duration of installations and availability of key components or installation personnel.

Scientific Instruments operating earnings for the ~~second~~first quarter of fiscal year 2010 included $1.8 million of costs resulting from the pending acquisition by Agilent, acquisition-related intangible amortization of $1.8 million and restructuring and other related costs of $0.7 million. In comparison, Scientific Instruments operating earnings for the first quarter of fiscal year 2009 included acquisition-related intangible amortization of ~~$1.7~~$2.1 million and restructuring and other related costs of $6.2 million. In comparison, Scientific Instruments operating earnings for the second quarter of fiscal year 2008 included acquisition-related intangible amortization of $1.9 million, amortization of $0.1 million related to inventory written up to fair value in connection with the acquisition of certain assets and liabilities of Analogix, Inc. (the “Analogix Business”) and restructuring and other related costs of $0.5$1.6 million. Excluding the impact of these items, operating earnings decreased as a percentage of sales ~~decreased slightly~~primarily due to the negative impact of product mix and lower average selling prices for certain analytical instruments products and the weaker U.S. dollar (which was favorable to reported sales ~~volume, largely~~but unfavorable to reported operating margins), partially offset by ~~the positive impact of efficiency improvements implemented in recent years, the benefits from~~ cost reduction activities implemented ~~during~~in the second quarter of fiscal year 2009 and the stronger U.S. dollar (which was unfavorable to reported sales but favorable to reported operating margins). Also, the second quarter of fiscal year 2008 included higher than usual costs related to new product introductions.2009.

Vacuum Technologies. The decrease in Vacuum Technologies sales was driven mainly by lower sales volume of products for both industrial and life science applications, primarily due to the impact of ~~the~~ continued global economic weakness on capital equipment spending, ~~and~~partly offset by the ~~negative~~positive impact of the ~~stronger~~weaker U.S. dollar on reported revenues.

~~Vacuum Technologies operating earnings for the second quarter of fiscal year 2009 included the impact of restructuring and other related costs of $0.8 million. Excluding the impact of these costs, the~~

Technologies operating earnings as a percentage of sales was primarily due to the positive impact of ~~efficiency improvements implemented in recent years, the benefits from~~ cost reduction activities implemented in the second quarter of fiscal year 2009, ~~and the stronger U.S. dollar,~~ partially offset by the negative impact of lower sales ~~volume.~~volume and the weaker U.S. dollar (which was favorable to reported sales but unfavorable to reported operating margins).

The following table presents comparisons of our sales and other selected consolidated financial results for the ~~second quarters~~first quarter of fiscal years ~~2009~~2010 and ~~2008:~~2009:


																Fiscal Quarter Ended
	Fiscal Quarter Ended										Increase (Decrease)					January 1, 2010					January 2, 2009					Increase (Decrease)
	April 3, 2009					March 28, 2008					Increase (Decrease)								% of					% of
	$			% of Sales		$			% of Sales		$			%		$			Sales		$			Sales		$			%
(dollars in millions, except per share data)
Sales	$	205.4		100.0	%	$	248.2		100.0	%	$	(42.8	)	(17.2	)%
Sales:																$	201.2		100.0	%	$	208.2		100.0	%	$	(7.0	)	(3.4	)%

Gross profit		89.5		43.6			112.9		45.5			(23.4	)	(20.7	)		86.9		43.2			95.3		45.8			(8.4	)	(8.9	)

Operating expenses:
Selling, general and administrative		59.3		28.9			67.6		27.3			(8.3	)	(12.3	)		59.9		29.8			60.9		29.2	%		(1.0	)	(1.7	)
Research and development		14.7		7.2			18.2		7.3			(3.5	)	(18.9	)		14.5		7.2			14.5		7.0			—		—

Total operating expenses		74.0		36.1			85.8		34.6			(11.8	)	(13.7	)		74.4		37.0			75.4		36.2			(1.0	)	(1.3	)

Operating earnings		15.5		7.5			27.1		10.9			(11.6	)	(42.8	)		12.5		6.2			19.9		9.6			(7.4	)	(37.4	)
Impairment of private company equity investment		—		—			(3.0	)	(1.2	)		3.0		100.0
Interest income		0.3		0.2			1.7		0.7			(1.4	)	(80.7	)		0.5		0.3			0.5		0.3			—		—
Interest expense		(0.3	)	(0.2	)		(0.4	)	(0.2	)		0.1		(22.9	)		(0.3	)	(0.2	)		(0.3	)	(0.2	)		—		—
Income tax expense		(5.3	)	(2.5	)		(9.6	)	(3.8	)		4.3		44.6			(4.6	)	(2.3	)		(7.1	)	(3.4	)		2.5		35.6

Net earnings	$	10.2		5.0	%	$	15.8		6.4	%	$	(5.6	)	(35.5	)%	$	8.1		4.0	%	$	13.0		6.3	%	$	(4.9	)	(38.1	)%

Net earnings per diluted share	$	0.35				$	0.52				$	(0.17	)			$	0.28				$	0.45				$	(0.17	)

Sales. As discussed under the headingSegment Results above, sales by our Scientific Instruments and Vacuum Technologies segments in the ~~second~~first quarter of fiscal year ~~2009~~2010 decreased by ~~16.4%~~3.0% and ~~21.0%~~5.0%, respectively, compared to the prior-year quarter. On a consolidated basis, sales declined ~~17.2%~~3.4% in the ~~second~~first quarter of fiscal year ~~2009.~~2010. This decrease was primarily ~~related to lower sales volume of a broad range of our analytical instruments and vacuum products~~ due to the impact of continued global economic weakness on capital equipment ~~spending.~~spending and by customers’ uncertainty and employee and other disruptions related to the announcement and pendency of the acquisition by Agilent. Reported sales were ~~also negatively~~positively impacted by the ~~stronger~~weaker U.S. dollar, which ~~strengthened~~weakened approximately 6%5% on a weighted-average basis compared to most major currencies in which we sell products and services. ~~Sales from businesses acquired in fiscal year 2008 positively impacted reported sales by approximately 1%.~~

For geographic reporting purposes, we ~~use~~refer to four ~~regions—~~regions – North America (excluding Mexico), Europe (including the Middle East and Africa), Asia Pacific (including India) and Latin America (including Mexico). Sales by geographic region in the ~~second~~first quarters of fiscal years ~~2009~~2010 and ~~2008~~2009 were as follows:


	Fiscal Quarter Ended								Increase (Decrease)					Fiscal Quarter Ended
	April 3, 2009				March 28, 2008				Increase (Decrease)					January 1, 2010				January 2, 2009				Increase (Decrease)
	$		% of Sales		$		% of Sales		$			%		$		% of Sales		$		% of Sales		$			%
(dollars in millions)
Geographic Region
North America	$	66.4	32.4	%	$	72.7	29.3	%	$	(6.3	)	(8.6	)%	$	62.4	31.0	%	$	65.2	31.3	%	$	(2.8	)	(4.3	)%
Europe		77.9	37.9			105.0	42.3			(27.1	)	(25.8	)		80.1	39.8			83.9	40.3			(3.8	)	(4.5	)
Asia Pacific		48.4	23.5			53.8	21.7			(5.4	)	(10.0	)		46.9	23.3			47.1	22.6			(0.2	)	(0.5	)
Latin America		12.7	6.2			16.7	6.7			(4.0	)	(23.8	)		11.8	5.9			12.0	5.8			(0.2	)	(2.4	)

Total company	$	205.4	100.0	%	$	248.2	100.0	%	$	(42.8	)	(17.2	)%	$	201.2	100.0	%	$	208.2	100.0	%	$	(7.0	)	(3.4	)%

~~Sales volume decreased~~The decrease in sales in all ~~geographic~~ regions ~~for both Scientific Instruments and Vacuum Technologies products~~was primarily ~~due~~attributable to the negative impact of ~~the~~ continued global economic weakness on capital equipment ~~spending. In addition, reported~~spending and the negative impact of customers’ uncertainty and employee and other disruptions related to the announcement and pendency of the acquisition by Agilent. Reported sales outside North America were ~~unfavorably~~favorably impacted by the ~~strengthening~~weakening of the U.S. dollar compared to the ~~second quarter of fiscal~~prior year ~~2008.~~quarter.

Gross Profit. Gross profit for the ~~second~~first quarter of fiscal year ~~2009~~2010 reflects the impact of ~~$1.5~~$1.6 million in amortization expense relating to acquisition-related intangible assets and ~~$2.3~~$0.2 million in restructuring and other related costs. In comparison, gross profit for the ~~second~~first quarter of fiscal year ~~2008~~2009 reflects the impact of ~~$1.5~~$1.6 million in amortization expense relating to acquisition-related intangible assets ~~amortization of $0.1 million related to inventory written up to fair value primarily in connection with the acquisition of the Analogix Business~~ and ~~$0.2~~$0.9 million in restructuring and other related costs. Excluding the impact of these items, ~~the decrease in~~ gross profit as a percentage of sales ~~was~~decreased primarily due to product mix, lower average selling prices of certain analytical instruments products, and the ~~negative~~ impact of ~~lower sales volume, partially offset by~~ the ~~stronger~~weaker U.S. dollar (which was ~~favorable~~unfavorable to reported gross profit, ~~margins~~ but ~~unfavorable~~favorable to reported sales), the positive impact of efficiency improvements (such as those resulting from lower-cost manufacturing and outsourcing initiatives, global procurement initiatives, and facility relocations/closures) implemented in recent years, and the benefits from partially offset by cost reduction activities implemented in the second quarter of fiscal year 2009.

Selling, General and Administrative. Selling, general and administrative expenses for the ~~second~~first quarter of fiscal year ~~2009~~2010 included $3.2 million of costs resulting from the pending acquisition by Agilent, $0.2 million in amortization expense relating to acquisition-related intangible assets and ~~$3.8~~$0.1 million in restructuring and other related costs. In comparison, selling, general and administrative expenses for the ~~second~~first quarter of fiscal year ~~2008~~2009 included ~~$0.4~~$0.5 million in amortization expense relating to acquisition-related intangible assets and ~~$0.2~~$0.6 million in restructuring and other related costs. Excluding the impact of these items, the ~~slight decrease in~~ selling, general and administrative expenses as a percentage of sales ~~was primarily~~declined due to cost reduction activities implemented in the ~~favorable~~second quarter of fiscal year 2009, partly offset by the unfavorable impact of the ~~stronger~~weaker U.S. ~~dollar and the cost savings achieved from restructuring activities implemented in recent years, partially offset by the negative impact of lower sales volume.~~dollar.

Research and Development. Research and development expenses for the ~~second~~first quarter of fiscal year ~~2009~~2010 reflect the impact of restructuring and other related costs of ~~$0.9~~$0.4 million. In comparison, research and development expenses for the ~~second~~first quarter of fiscal year ~~2008~~2009 reflect the impact of restructuring and other related costs of $0.2 million. Excluding the impact of these items, ~~the decrease in~~ research and development expenses as a percentage of sales ~~was primarily due~~were essentially flat compared to the ~~favorable impact of the stronger U.S. dollar in the second~~first quarter of fiscal ~~year 2009 and higher costs associated with new product introductions in the second quarter of fiscal year 2008.~~2009.

Restructuring Activities. We have committed to several restructuring plans in order to improve operational efficiencies, centralize functions, reallocate resources and reduce operating costs.From the respective inception dates of these plans through ~~April 3, 2009,~~January 1, 2010, we have incurred a total of ~~$13.4~~$12.2 million in restructuring expense and a total of ~~$7.7~~$10.6 million in other costs related directly to those plans (comprised primarily of employee

retention and relocation costs and accelerated depreciation of assets disposed upon the closure of facilities). Of the $10.6 million in other restructuring-related costs, $0.7 million was recorded in the first quarter of fiscal year 2010 which was primarily related to the fiscal year 2007 restructuring plan.

The following table sets forth changes in ~~our~~the Company’s aggregate liability relating to all ongoing restructuring plans during ~~the second quarter of fiscal year 2009:~~

~~Fiscal Year 2009 Second Quarter Plan.~~ During the second quarter of fiscal year 2009, we committed to a plan to reduce our cost structure, primarily through headcount reductions, due to continuing uncertainties in the global economic environment. The plan involves the elimination of approximately 240 regular employees (primarily in North America and Europe and to a lesser extent Asia Pacific and Latin America) and 80 temporary positions in both the Scientific Instruments and Vacuum Technologies segments. In addition, the plan includes the closure of one small R&D/manufacturing facility in North America (Lake Forest, California) and two sales offices in Europe (Sweden and Switzerland). We expect these activities to be completed during fiscal year 2009.

Restructuring and other related costs to be incurred in connection with this plan are currently estimated to be between $8.5 million and $10.5 million, of which between $8.0 million and $9.5 million is expected to impact the Scientific Instruments segment and between $0.5 million and $1.0 million is expected to impact the Vacuum Technologies segment. The restructuring costs include one-time termination benefits for employees whose positions are being eliminated of between $7.5 million and $9.0 million and lease termination costs of between $0.1 million and $0.2 million (including future lease payments on vacated facilities). Other restructuring-related costs include employee retention and relocation costs of between $0.3 million and $1.0 million and facility-related relocation costs and accelerated depreciation of fixed assets to be disposed upon the closure of facilities of between $0.1 million and $0.3 million. Costs relating to restructuring activities recorded under this plan have been included in cost of sales, selling, general and administrative expenses and research and development expenses.

The following table sets forth changes in our restructuring liability relating to the foregoing plan during the second quarter of fiscal year 2009 as well as total restructuring expense and other restructuring-related costs recorded since the inception of the plan:

The restructuring expense of $6.4 million recorded during the second quarter of fiscal year 2009 related to employee termination benefits, of which $5.7 million impacted the Scientific Instruments segment and $0.7 million impacted the Vacuum Technologies segment. We also incurred $0.3 million in other restructuring-related costs during the quarter, which impacted the Scientific Instruments segment and were comprised of $0.1 million in employee-related costs and a $0.2 million non-cash charge for accelerated depreciation of assets to be disposed upon the closure of facilities. Most of these costs are expected to be settled during fiscal year 2009, although certain one-time termination benefits are expected to be settled in fiscal year 2010.

~~Fiscal Year 2009 First Quarter Plan.~~ ~~During~~ the first quarter of fiscal year 2009, we committed to a separate plan to reduce our employee headcount in order to reduce operating costs and increase margins. The plan involves the termination of approximately 35 employees, mostly located in Europe. The restructuring costs related to this plan primarily consist of one-time termination benefits which are expected to be settled by the end of fiscal year 2010. This restructuring plan did not involve any non-cash components. Costs relating to restructuring activities recorded under this plan have been included in cost of sales, selling, general and administrative expenses and research and development expenses.

~~The following table sets forth changes in our restructuring liability relating to the foregoing plan during the second quarter of fiscal year 2009:~~2010:

~~Fiscal Year 2007 Plan~~. During the third quarter of fiscal year 2007, we committed to a plan to combine and optimize the development and assembly of most of our nuclear magnetic resonance (“NMR”) and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies. As part of the plan, we are creating an information rich detection (“IRD”) center in Walnut Creek, California, where NMR operations are being integrated with mass spectrometry operations already located in Walnut Creek. Merging our IRD talent base into this single location will capitalize on our strength in NMR and mass spectrometry and enhance our ability to develop innovative IRD solutions that are more powerful, complementary, routine and user-friendly. Underscoring our commitment to IRD and the benefits that a combined location and organization will provide, we are investing in a new 45,000 square foot building and a substantial remodel of an existing building there to house the IRD center.

As a result of the plan, a number of employee positions have been or will be relocated or eliminated and certain facilities have been, or will be, consolidated. These actions primarily impact the Scientific Instruments segment and involve the elimination of between approximately 40 and 60 positions. We expect these activities to be completed during fiscal year 2009.

Restructuring and other related costs associated with this plan include one-time employee termination benefits, employee retention payments, costs to relocate facilities (including decommissioning costs, moving costs and temporary facility/storage costs), accelerated depreciation of fixed assets to be disposed as a result of facilities actions and lease termination costs.

The net reversals of restructuring expense of $0.1 million recorded during the second quarter of fiscal year 2009 were primarily due to the early cancellation of our lease agreement for a vacated facility partially offset by additional employee termination benefits. We also incurred $0.5 million in other restructuring-related costs during the quarter, which were comprised of $0.3 million in employee retention costs and $0.2 million in facilities-related costs including decommissioning costs and a non-cash charge for accelerated depreciation of assets to be disposed upon the closure of facilities.

Restructuring Cost Savings. The following table sets forth the estimated annual cost savings for each plan, when they were initiated, as well as where those cost savings were expected to be realized:

These estimated cost savings are expected to impact cost of sales, selling, general and administrative expenses and research and development expenses. Some of these cost savings have been and will continue to be reinvested in other parts of our business, for example, as part of our continued emphasis on IRD and consumable products. In addition, unrelated cost increases in other areas of our operations have and could in the future offset some or all of these cost savings. Although it is difficult to quantify with any precision our actual cost savings to date from these activities, ~~many~~some of which are still ongoing, we currently believe that the ultimate savings realized will not differ materially from these estimates.

~~Impairment of Private Company Equity Investment.~~During the second quarter of fiscal year 2008, we became aware of information which raised substantial doubt about the ability of a small, private company in which we held a cost-method equity investment to continue as a going concern. Based on this information, we determined that the fair value of our investment had declined and that the decline was other-than-temporary. As a result, we wrote off the entire $3.0 million carrying value via an impairment charge in the quarter.

~~Interest Income.~~~~The decrease in interest income was primarily due to lower interest rates on invested cash during the second quarter of fiscal year 2009 compared to the second quarter of fiscal year 2008.~~

Income Tax ~~Expense.~~Expense. The effective income tax rate was ~~34.3%~~36.2% for the second quarter of fiscal year 2009, compared to 37.8% for the second quarter of fiscal year 2008. The lower effective income tax rate in the second quarter of fiscal year 2009 was primarily due to lower U.S. taxes on foreign earnings and lower non-deductible compensation expense.

~~Net Earnings~~. Net earnings for the second quarter of fiscal year 2009 reflect the after-tax impacts of $1.7 million in pre-tax acquisition-related intangible amortization and $7.0 million in pre-tax restructuring and other related costs. Net earnings for the second quarter of fiscal year 2008 reflect the after-tax impacts of a $3.0 million impairment of a private company equity investment, $1.9 million in acquisition-related intangible amortization, $0.1 million in amortization related to inventory written up to fair value in connection with the acquisition of the Analogix Business and $0.5 million in restructuring and other related costs. Excluding the after-tax impact of these items, the decrease in net earnings in the second quarter of fiscal year 2009 was primarily attributable to the negative impact of lower sales volume.

~~First Six Months of Fiscal Year 2009 Compared to First Six Months of Fiscal Year 2008~~

The following table presents comparisons of our sales and operating earnings for each of our Scientific Instruments and Vacuum Technologies segments and in total for the first six months of fiscal years 2009 and 2008:

~~Scientific Instruments~~. The decrease in Scientific Instruments sales was primarily attributable to lower sales volume of a broad range of our products and the negative impact of the stronger U.S. dollar on reported revenues. The lower volume was primarily due to the impact of the continued global economic weakness on capital equipment spending. Sales from businesses acquired in fiscal year 2008 positively impacted reported sales by approximately 1%.

Scientific Instruments operating earnings for the first six months of fiscal year 2009 included acquisition-related intangible amortization of $3.8 million and restructuring and other related costs of $7.8 million. In comparison, Scientific Instruments operating earnings for the first six months of fiscal year 2008 included acquisition-related intangible amortization of $3.7 million, amortization of $0.6 million related to inventory written up in connection with the acquisitions of IonSpec Corporation and of the Analogix Business,

restructuring and other related costs of $2.5 million. Excluding the impact of these items, operating earnings decreased as a percentage of sales due to the negative impact of lower sales volume, partially offset by efficiency improvements implemented in recent years, the benefits of cost reduction activities implemented during the second quarter of fiscal year 2009 and the stronger U.S. dollar (which was unfavorable to reported sales but favorable to reported operating margins).

~~Vacuum Technologies~~. The decrease in Vacuum Technologies sales was driven mainly by lower sales volume of products for industrial applications, primarily due to the impact of the continued global economic weakness on capital equipment spending and by the negative impact of the stronger U.S. dollar on reported revenues.

Vacuum Technologies operating earnings for the first six months of fiscal year 2009 included the impact of restructuring and other related costs of $0.9 million. Excluding the impact of these costs, the increase in Vacuum Technologies operating earnings as a percentage of sales was primarily due to the positive impact of efficiency improvements implemented in recent years, cost reduction activities implemented during the second quarter of fiscal year 2009 and the stronger U.S. dollar, partially offset by the negative impact of lower sales volume.

~~The following table presents comparisons of our sales and other selected consolidated financial results for the first six months of fiscal years 2009 and 2008:~~

~~Sales.~~ ~~As discussed under the heading~~~~Segment Results~~ above, sales by our Scientific Instruments and Vacuum Technologies segments in the first six months of fiscal year 2009 decreased by 14.6% and 15.7%, respectively, compared to the first six months of fiscal year 2008. On a consolidated basis, sales declined 14.8% in the first six months of fiscal year 2009. This decrease was primarily related to lower sales volume of a broad range of our products due to the impact of the continued global economic weakness on capital equipment spending. Reported sales were also negatively impacted by the stronger U.S. dollar, which strengthened approximately 6% on a weighted-average basis compared to all currencies in which we sell products and services. Sales from businesses acquired in fiscal year 2008 positively impacted reported sales by approximately 1%.

~~Sales by geographic region in the first six months of fiscal years 2009 and 2008 were as follows:~~

Sales volume decreased in all geographic regions for both Scientific Instruments and Vacuum Technologies products primarily due to the impact of the continued global economic weakness on capital equipment spending. In addition, reported sales outside North America were unfavorably impacted by the strengthening of the U.S. dollar compared to the first six months of fiscal year 2008.

~~Gross Profit~~. Gross profit for the first six months of fiscal year 2009 reflects the impact of $3.1 million in amortization expense relating to acquisition-related intangible assets and $3.2 million in restructuring and other related costs. In comparison, gross profit for the first six months of fiscal year 2008 reflects the impact of $2.9 million in amortization expense relating to acquisition-related intangible assets, amortization of $0.6 million related to inventory written up to fair value primarily in connection with the IonSpec Corporation and Analogix Business acquisitions and $0.7 million in restructuring and other related costs. Excluding the impact of these items, gross profit as a percentage of sales was basically flat. The favorable impacts of the stronger U.S. dollar (which was favorable to reported gross profit margins but unfavorable to reported sales), the positive impact of efficiency improvements (such as those resulting from lower-cost manufacturing and outsourcing initiatives, global procurement initiatives, and facility relocations/closures) implemented in recent years, and the benefits from cost reduction activities implemented in the second quarter of fiscal year 2009 were offset by the negative impact of lower sales volume.

~~Selling, General and Administrative.~~ Selling, general and administrative expenses for the first six months of fiscal year 2009 included $0.7 million in amortization expense relating to acquisition-related intangible assets and $4.4 million in restructuring and other related costs. In comparison, selling, general and administrative expenses for the first six months of fiscal year 2008 included $0.8 million in amortization expense relating to acquisition-related intangible assets and $1.4 million in restructuring and other related costs. Excluding the impact of these items, the increase in selling, general and administrative expenses as a percentage of sales was primarily due to the negative impact of lower sales volume, partially offset by the favorable impact of the stronger U.S. dollar and the cost savings achieved from restructuring activities implemented in recent years.

~~Research and Development~~. Research and development expenses for the first six months of fiscal year 2009 reflect the impact of restructuring and other related costs of $1.1 million. In comparison, research and development expenses for the first six months of fiscal year 2008 reflect the impact of restructuring and other related costs of $0.5 million. Excluding the impact of these items, the decrease in research and development expenses as a percentage of sales was primarily due to the favorable impact of the stronger U.S. dollar in the first six months of fiscal year 2009 and higher costs associated with new product introductions in the first six months of fiscal year 2008.

~~Restructuring Activities~~~~. We have committed to several restructuring plans in order to improve operational efficiencies, centralize functions, reallocate resources and reduce operating costs.From the respective inception~~

dates of these plans through April 3, 2009, we have incurred a total of $13.4 million in restructuring expense and a total of $7.7 million in other costs related directly to those plans (comprised primarily of employee retention and relocation costs and accelerated depreciation of assets disposed upon the closure of facilities).

~~The following table sets forth changes in our aggregate liability relating to all restructuring plans during the first six months of fiscal year 2009:~~

The following table sets forth changes in our restructuring liability relating to the foregoing plan during the first six months of fiscal year 2009 as well as total restructuring expense and other restructuring-related costs recorded since the inception of the plan:

The restructuring expense of $6.4 million recorded during the first six months of fiscal year 2009 related to employee termination benefits of which $5.7 million impacted the Scientific Instruments segment and $0.7 million impacted the Vacuum Technologies segment. We also incurred $0.3 million in other restructuring-related costs during the period, which impacted the Scientific Instruments segment and were comprised of $0.1 million in employee-related costs and a $0.2 million non-cash charge for accelerated depreciation of assets to be disposed upon the closure of facilities. Most of these costs are expected to be settled during fiscal year 2009, although certain one-time termination benefits are expected to be settled in fiscal year 2010.

~~Fiscal Year 2009 First Quarter Plan.~~ ~~During~~ the first quarter of fiscal year ~~2009, we committed~~2010, compared to ~~a separate plan to reduce our employee headcount in order to reduce operating costs and increase margins.~~

~~The following table sets forth changes in our restructuring liability relating to~~35.3% for the ~~foregoing plan during the~~ first ~~six months of fiscal year 2009:~~

The restructuring expense of $1.3 million recorded during the first six months of fiscal year 2009 related to employee termination benefits of which $1.2 million impacted the Scientific Instruments segment and $0.1 million impacted the Vacuum Technologies segment.

~~Fiscal Year 2007 Plan~~~~. During the third~~ quarter of fiscal year 2007, we committed to a plan to combine and optimize the development and assembly of most of our nuclear magnetic resonance (“NMR”) and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies.

2009. The following table sets forth changes in our restructuring liability relating to the foregoing plan during the first six months of fiscal year 2009 as well as total restructuring expense and other restructuring-related costs recorded since the inception of the plan:

The reversals of restructuring expense of $0.5 million recorded during the second quarter of fiscal year 2009 related to changes in estimates relating to certain employee termination benefits and the early cancellation of our lease agreement for a vacated facility. We also incurred $1.2 million in other restructuring-related costs during the quarter, which were comprised of $0.9 million in employee retention costs and $0.3 million in facilities-related costs including decommissioning costs and a non-cash charge for accelerated depreciation of assets to be disposed upon the closure of facilities.

~~Impairment of Private Company Equity Investment.~~During the first six months of fiscal year 2008, we became aware of information which raised substantial doubt about the ability of a small, private company in which we held a cost-method equity investment to continue as a going concern. Based on this information, we determined that the fair value of our investment had declined and that the decline was other-than-temporary. As a result, we wrote off the entire $3.0 million carrying value via an impairment charge in the period.

~~Interest Income.~~The decrease in interest income was primarily due to lower interest rates and lower average invested cash balances during the first six months of fiscal year 2009 compared to the first six months of fiscal year 2008.

~~Income Tax Expense.~~~~The~~higher effective ~~income tax rate was 34.9% for the first six months of fiscal year 2009, compared to 34.6% for the first six months of fiscal year 2008. The lower effective income~~ tax rate in the first ~~six months~~quarter of fiscal year ~~2008~~2010 was primarily due to the ~~release~~expiration of ~~$1.5 million in~~the U.S. federal research and development tax ~~reserves resulting from the positive outcome of tax uncertainties, largely offset by higher U.S. taxes on foreign earnings and higher non-deductible compensation expense during fiscal year 2008.~~credit.

Net Earnings. Net earnings for the first ~~six months~~quarter of fiscal year ~~2009~~2010 reflect the after-tax impacts of ~~$3.8~~$3.2 million of pre-tax costs resulting from the pending acquisition by Agilent, $1.8 million in pre-tax acquisition-related intangible amortization and ~~$8.7~~$0.7 million in pre-tax restructuring and other related costs. Net earnings for the first ~~six months~~quarter of fiscal year ~~2008~~2009 reflect the after-tax impacts of ~~an impairment of a private company equity investment of $3.0 million, $3.7~~$2.1 million in acquisition-related intangible amortization ~~$0.6 million in amortization related to inventory written up to fair value in connection with the acquisitions of IonSpec Corporation~~ and ~~the Analogix Business and $2.6~~$1.7 million in restructuring and other related costs. Excluding the after-tax impact of these items, the decrease in net earnings in the first ~~six months~~quarter of fiscal year ~~2009~~2010 was primarily attributable to ~~the negative impact~~lower gross profits as a percentage of ~~lower sales volume.~~sales.

The diversity of our products, the applications we serve and our worldwide distribution position us well. However, we ~~are operating~~continue to operate in difficult global economic conditions. The uncertainty of these conditions, as well as customers’ uncertainty and ~~are facing unprecedented economic uncertainties~~employee and other disruptions related to the announcement and pendency of our acquisition by Agilent and related divestitures being undertaken in order to obtain regulatory approval of that acquisition, make it difficult for us to project our near-term results of operations. We experienced a year-over-year decline in customer orders at the end of our first quarter of fiscal year 2009, which weakness continued to a lesser extent through the second quarter of fiscal year 2009. We currently expect this order weakness and corresponding declines in revenue and earnings compared to fiscal year 2008 to continue for the remainder of the fiscal year. These conditions could ~~nonetheless worsen~~further impact our business and have an adverse effect on our financial position, results of operations ~~and/~~or cash flows. In addition, we have incurred and will continue to incur legal and other expenses in connection with the pending acquisition by Agilent, which could have an adverse effect on our financial position, results of operations or cash flows.

We generated ~~$50.5~~$22.7 million of cash from operating activities in the first ~~six months~~quarter of fiscal year ~~2009,~~2010, compared to ~~$29.7~~$16.9 million generated in the first ~~six months~~quarter of fiscal year ~~2008.~~2009. The increase in operating cash flows was primarily due to ~~the favorable impact of decreased accounts receivable~~increased advance payments from customers, reduced inventory purchases, and ~~inventory balances, partially offset by decreased~~increased net earnings after adjustments for ~~non-cash~~noncash income and expenses ~~and~~partly offset by decreased ~~inventory related liabilities. The decrease in accounts receivable was primarily related~~cash collections (due to ~~the level and timing of invoicing and collections. Inventory balances have declined primarily due to reduced inventory purchases to align with current revenue levels.~~lower prior-quarter revenues).

We used ~~$12.1~~$3.4 million of cash for investing activities in the first ~~six months~~quarter of fiscal year ~~2009,~~2010, which compares to ~~$23.6~~$2.5 million used for investing activities in the first ~~six months~~quarter of fiscal year ~~2008. The decrease in cash used for investing activities was primarily~~2009. In the ~~result~~first quarter of ~~lower acquisition-related~~fiscal year 2009, we received a $5.0 million non-refundable first surrender payment ~~activity and cash received for the surrender of a building sublease, partially offset by increased capital expenditures. In October 2008, we entered into~~under an agreement with VMS ~~under~~in which we agreed to surrender to them the sublease for our facility in Palo Alto, ~~California~~CA in exchange for $21.0 million. ~~We received a $5.0 million non-refundable first surrender payment under this agreement in the first quarter of fiscal year 2009 and will receive the~~The remaining $16.0 million is due when we fully surrender the facility in the third quarter of fiscal year 2010. ~~The higher capital~~

~~expenditures during~~Excluding the first ~~six months~~surrender payment, cash used for investing activities decreased $4.1 million in the first quarter of fiscal year ~~2009 were~~2010 compared to the same period in the prior year primarily due to reduced capital spending levels, as we have completed the majority of our spending related to the construction of our ~~new~~ IRD facility in Walnut Creek, ~~California. The higher~~partially offset by $1.3 million of cash ~~used for acquisition-related payments~~paid in ~~the first six months of fiscal year 2008 consisted primarily of consideration for~~connection with the acquisition of ~~the~~certain net assets of Analogix, ~~Business in November 2007.~~Inc. (the “Analogix Business”).

We ~~used $5.5~~generated $1.6 million of cash ~~for~~from financing activities in the first ~~six months~~quarter of fiscal year ~~2009,~~2010, which compares to ~~$55.7~~$0.5 million ~~used for~~generated by financing activities in the first ~~six months~~quarter of fiscal year ~~2008.~~2009. Cash ~~used for~~generated from financing activities in the first ~~six months~~quarter of fiscal year ~~2009~~2010 was lower primarily as a result of lower expenditures to repurchase and retire common stock (such expenditures were made in both periods as a result of an effort to reduce the number of outstanding common shares) and by lower proceeds from the issuance of common stockhigher due to ~~lower~~higher stock option exercise volume.

We maintain relationships with banks in many countries from whom we sometimes obtain bank guarantees and short-term standby letters of credit. These guarantees and letters of credit relate primarily to advance payments and deposits made to our subsidiaries by customers for which separate liabilities are recorded in the unaudited condensed consolidated financial statements. As of ~~April 3, 2009,~~January 1, 2010, a total of ~~$18.1~~$13.8 million of these bank guarantees and letters of credit were outstanding. No amounts had been drawn by beneficiaries under these or any other outstanding guarantees or letters of credit as of that date.

As of both ~~April 3, 2009~~January 1, 2010 and October ~~3, 2008,~~2, 2009, we had an $18.8 million term loan outstanding with a U.S. financial institution at a fixed interest rate of 6.7%. The term loan contains certain covenants that limit future borrowings and the payment of cash dividends and require the maintenance of certain levels of working capital and operating results. We were in compliance with all restrictive covenants of the term loan agreement at ~~April 3, 2009.~~

In connection with certain acquisitions, we have accrued a portion of the purchase price that has been retained to secure the sellers’ indemnification obligations. As of April 3, 2009, we had retained an aggregate of $1.6 million, which will become payable (net of any indemnification claims) between April and November 2009.January 1, 2010.

As of ~~April 3, 2009,~~January 1, 2010, we had several outstanding contingent consideration arrangements relating to acquired businesses. Amounts subject to these arrangements can be earned over the respective measurement period, depending on the performance of the acquired business relative to certain financial ~~and/~~or operational targets.

The following table summarizes contingent consideration arrangements as of ~~April 3, 2009:~~January 1, 2010:

We also have an outstanding contingent consideration arrangement related to the purchase of certain assets. Remaining maximum contingent amounts under this arrangement were $2.6 million as of January 1, 2010.

During the ~~second~~first quarter of fiscal year ~~2009, our contingent consideration measurement period~~2010, we made a cash payment of $1.3 million which was accrued as part of the purchase price to secure the seller’s indemnification obligations in connection with ~~IonSpec Corporation ended and approximately $0.2 million was recorded as a liability related to this arrangement.~~the acquisition of the Analogix Business in fiscal year 2007.

The Distribution Agreement provides that we are responsible for certain litigation to which VAI was a party, and further provides that we will indemnify VMS and VSEA for one-third of the costs, expenses and other liabilities relating to certain discontinued, former and corporate operations of VAI, including certain environmental liabilities (see Note 13 of the Notes to the Unaudited Condensed Consolidated Financial Statements).

As of April 3, 2009, we had cancelable commitments to a contractor for capital expenditures totaling approximately $6.2 million relating to the construction of our new IRD center in Walnut Creek, California. In the event that these commitments are canceled for reasons other than the contractor’s default, we may be responsible for reimbursement of actual costs incurred by the contractor. We had no material cancelable or non-cancelable commitments for capital expenditures as of ~~April 3, 2009.~~January 1, 2010. In the aggregate, we currently anticipate that our capital expenditures will be ~~approximately 2.5% to 3.0%~~less than 2.0% of sales for fiscal year ~~2009.~~

~~As discussed above under the heading~~~~Restructuring Activities~~, in April 2007, we committed to a plan to combine and optimize the development and assembly of most of our NMR and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies. In connection with this plan, we expect to make capital expenditures of approximately $30 million, of which $21.8 million has been spent through April 3, 2009. These capital expenditures began in the fourth quarter of fiscal year 2007 and will continue through fiscal year 2009.

In connection with all of our restructuring plans, we expect to make cash payments for restructuring and other related costs totaling between approximately $10 million and $14 million during fiscal year 2009, of which $6.3 million was paid during the first six months of fiscal year 2009.

The Company has outstanding contingent consideration arrangements related to an Asset Purchase Agreement. Remaining maximum contingent amounts under this agreement were $2.6 million as of April 3, 2009.2010.

In February 2008, our Board of Directors approved a stock repurchase program under which we are authorized to utilize up to $100 million to repurchase shares of our common stock. During the first quarter of fiscal year 2010, we did not purchase any shares under this authorization. This repurchase program ~~is effective through~~expired on December 31, 2009. During the first six months of fiscal year 2009, we repurchased and retired 344,100 shares under this authorization at an aggregate cost of $7.1 million. As of April 3, 2009, we had remaining authorization to repurchase $37.5 million of our common stock under this repurchase program.

Our liquidity is affected by many other factors, ~~some based on the normal ongoing~~including on-going operations of our business, the pending acquisition by Agilent and ~~others related to~~ external economic conditions. Our liquidity has not been materially affected by the pending acquisition, the deterioration in the global financial markets or global economic conditions in general. However, ~~this deterioration has~~current financial and economic conditions could adversely ~~impacted~~impact the availability of credit to us as well as to our customers and suppliers.

We have no material exposure to market risk for changes in interest rates or investment valuations. Our outstanding debt carries a fixed interest rate, and we invest our excess cash primarily in depository accounts and money market funds at various financial institutions. While we have not historically needed to borrow to support working capital or capital expenditure requirements, there is no assurance that we might not need to borrow to support these requirements given global economic ~~conditions. This could also adversely affect our ability to complete acquisitions~~conditions and ~~repurchase our common stock.~~whether such financing would be available.

We nonetheless believe that cash generated from operations, together with our current cash and cash equivalents balances and current borrowing capability, will be sufficient to satisfy our cash requirements for the next 12 months. There can be no assurance, however, that our business will continue to generate cash flows at current levels or that credit will be available to us if and when needed. Future operating performance and our ability to obtain credit will be subject to future economic conditions ~~and to~~as well as financial, business and other ~~factors.~~factors, including the affects of the pendency of the acquisition by Agilent.

The following table summarizes the amount and estimated timing of future cash expenditures relating to principal and interest payments on outstanding long-term debt, minimum rentals due for certain facilities and other leased assets under long-term, non-cancelable operating leases and other long-term liabilities as of ~~April 3, 2009:~~January 1, 2010:


	Six Months Ending Oct. 2, 2009			Fiscal Years																				Nine Months Ending Oct. 1, 2010			Fiscal Years																	Total
			2010			2011			2012			2013			2014			Thereafter			Total			Nine Months Ending Oct. 1, 2010		2011			2012			2013			2014			2015			Thereafter			Total
(in thousands)	Six Months Ending Oct. 2, 2009
Operating leases	$	4,438		$	7,063		$	4,091		$	2,388		$	1,879		$	1,356		$	1,868		$	23,083	$	5,061		$	5,741		$	3,347		$	2,312		$	1,730		$	1,460		$	595	$	20,246
Long-term debt		—			6,250			—			6,250			—			6,250			—			18,750
Long-term debt (including current portion)																									6,250			—			6,250			—			6,250			—			—		18,750
Interest on long-term debt		627			1,152			838			733			419			314			—			4,083		838			838			733			419			314			—			—		3,142
Other long-term liabilities		—			7,800			4,292			3,922			2,932			2,679			21,244			42,869		—			5,592			3,550			2,929			2,805			2,593			25,511		42,980

Total	$	5,065		$	22,265		$	9,221		$	13,293		$	5,230		$	10,599		$	23,112		$	88,785	$	12,149		$	12,171		$	13,880		$	5,660		$	11,099		$	4,053		$	26,106	$	85,118

As of ~~April 3, 2009,~~January 1, 2010, we did not have any off-balance sheet commercial commitments that could result in a significant cash outflow upon the occurrence of some contingent event, except for contingent payments of up to a maximum of ~~$10.3~~$10.1 million related to acquisitions and $2.6 million related to ~~an Asset Purchase Agreement~~the purchase of certain assets as discussed underLiquidity and Capital Resources above, the specific amounts of which are not currently determinable.

In ~~September 2006, the FASB issued SFAS 157,~~ ~~Fair Value Measurements,~~~~which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. In February~~December 2008, the FASB issued ~~FASB Staff Position (“FSP”) 157-2,~~~~Effective Date~~additional disclosure requirements for plan assets of ~~FASB Statement No. 157,~~~~which delays~~a defined benefit pension or other postretirement plan. The required disclosures include a description of the ~~effective date~~Company’s investment policies and strategies, the fair value of ~~SFAS 157 for all nonfinancial~~each major category of plan assets, the inputs and valuation techniques used to measure the fair value of plan assets, the effect of fair value measurements using significant unobservable inputs on changes in plan assets and ~~nonfinancial liabilities to~~the significant concentrations of risk within plan assets. These additional disclosures are effective for annual disclosure for fiscal years ~~beginning~~ending after ~~November~~December 15, 2008, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). We adopted SFAS 157 effective October 4, 2008 with the exception of the application of the statement to nonrecurring nonfinancial assets and nonfinancial liabilities (see Note 4).2009. We do not expect the adoption of the ~~provisions deferred by FSP 157-2~~new disclosure requirements in fiscal year 2010 to have a material impact on our financial condition or results of operations.

In ~~December 2007,~~October 2009, the FASB issued ~~SFAS 141 (revised 2007),~~~~Business Combinations~~~~, (“SFAS 141(R)”). SFAS 141(R) retains the fundamental requirements of the original pronouncement requiring~~two new accounting standards that ~~the purchase method be used for all business combinations but also provides revised~~provide guidance for ~~recognizing and measuring identifiable assets and goodwill acquired, liabilities assumed, and any noncontrolling interest~~revenue recognition. The first standard revises guidance for arrangements with multiple deliverables. This accounting standard replaces the term fair value in the ~~acquiree. It also requires~~revenue recognition allocation guidance with selling price and establishes a hierarchy for determining the selling price of a deliverable. The selling price of each deliverable will first be based on vendor specific objective evidence (“VSOE”) if available, second on third-party evidence (“TPE”) if VSOE is not available and third on estimated selling price if neither VSOE nor TPE is available. In addition, the residual method is no longer permitted as vendors are now required to allocate arrangement consideration using the relative selling price method. The second new accounting standard excludes from the scope of software revenue recognition, software components contained in, and essential to the functionality of, ~~assets acquired~~tangible products. These two new accounting standards require expanded qualitative and ~~liabilities assumed arising from contingencies,~~quantitative disclosures and are effective for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. Early adoption is permitted. We do not expect the ~~capitalization~~adoption of ~~in-process research~~these accounting standards in the first quarter of fiscal year 2011 to have a material impact on our financial condition or results of operations.

In January 2010, the FASB issued an accounting standard update that clarifies and ~~development at~~provides additional disclosure requirements related to recurring and non-recurring fair value measurements and ~~the expensing of acquisition-related costs as incurred.SFAS 141(R) is~~employers’

disclosures about postretirement benefit plan assets. These additional disclosures are effective for ~~fiscal years~~interim and annual reporting periods beginning after December 15, ~~2008.~~2009. We do not expect ~~its~~our adoption of this accounting standard update in the ~~first~~second quarter of fiscal year 2010 to have a material impact on our financial condition or results of operations. However, in the event that we complete acquisitions subsequent to our adoption of SFAS 141(R), the application of its provisions will likely have a material impact on our results of operations, although we are not currently able to estimate that impact.

~~based on the recognition and measurement criteria of SFAS 5,~~~~Accounting for Contingencies.~~~~The adoption of FSP FAS 141(R)-1 could have a material impact on the results of our operations, although we are not currently able to estimate that impact.~~

~~In December 2007, the FASB issued SFAS 160,~~~~Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51~~. SFAS 160 requires that ownership interests in subsidiaries held by parties other than the parent and the amount of consolidated net income be clearly identified, labeled and presented in the consolidated financial statements. It also requires once a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary be initially measured at fair value. Sufficient disclosures are required to clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS 160 is effective for fiscal years beginning after December 15, 2008, and requires retroactive adoption of the presentation and disclosure requirements for existing minority interests. All other requirements are applied prospectively. We do not expect the adoption of SFAS 160 to have a material impact on our financial condition or results of operations.

~~In April 2008, the FASB issued FSP 142-3,~~~~Determination of the Useful Life of Intangible Assets~~, which amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset. The intent of FSP 142-3 is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142,~~Goodwill and Other Intangible Assets~~~~, and the period of expected cash flows used to measure the fair value of the asset under SFAS 141(R),~~~~Business Combinations~~, and other accounting literature. FSP 142-3 is effective for fiscal years beginning after December 15, 2008 and must be applied prospectively to intangible assets acquired after the effective date. Early adoption is prohibited. Given that FSP 142-3 applies to intangible assets acquired after the effective date, we do not expect its adoption to have a material impact on our financial condition or results of operations.

~~In June 2008, the FASB issued FSP EITF 03-6-1,~~~~Determining Whether Instruments Granted in Share-Based Payment Transactions are Participating Securities~~. FSP EITF 03-6-1 states that unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents are participating securities and shall be included in the computation of earnings per share under the two-class method described in SFAS 128,~~Earnings per Share~~. FSP EITF 03-6-1 is effective for fiscal years beginning after December 15, 2008, and interim periods within those years, on a retrospective basis. We do not expect the adoption of FSP EITF 03-6-1 to have a material impact on our earnings per share.

~~In December 2008, the FASB issued FSP 132(R)-1,~~~~Employers’ Disclosures about Postretirement Benefit Plan Assets~~~~. FSP 132(R)-1 amends SFAS 132 (revised 2003),~~~~Employers’ Disclosures about Pensions and Other Postretirement Benefits~~, to provide guidance on an employer’s disclosures about plan assets of a defined benefit pension or other postretirement plan. This FSP is effective for fiscal years ending after December 15, 2009. We do not expect the adoption of FSP 132(R)-1 to have a material impact on our financial condition or results of operations.

Foreign Currency Exchange Risk. We enter into foreign exchange forward contracts to minimize the short-term impact of foreign currency fluctuations on assets and liabilities denominated in non-functional currencies. From time to time, we also enter into foreign exchange forward contracts to minimize the impact of foreign currency fluctuations on forecasted transactions. The success of our hedging activities depends on our ability to forecast balance sheet exposures and transaction activity in various foreign currencies. To the extent that these forecasts are overstated or understated during periods of currency volatility, we could experience unanticipated currency gains or losses. However, we believe that in most cases any such gains or losses would be substantially offset by losses or gains from the related foreign exchange forward contracts. ~~We therefore~~Therefore, we believe that the direct effect of an immediate 10% change in the exchange rate between the U.S. dollar and all other currencies is not reasonably likely to have a material adverse effect on our financial condition or results of operations.

During the first ~~six months~~quarter of fiscal year ~~2009,~~2010, we were not party to any foreign exchange forward contracts designated as cash flow hedges of forecasted transactions.

Our foreign exchange forward contracts generally do not extend beyond one month in original maturity. A summary of all foreign exchange forward contracts that were outstanding as of ~~April 3, 2009~~January 1, 2010 follows:


	Notional Value Sold		Notional Value Purchased		Notional Value Sold		Notional Value Purchased
(in thousands)
Australian dollar	$	—	$	49,299	$	—	$	34,219
British pound						—		13,514
Euro		—		15,768		—		10,573
British pound		—		11,840
Japanese yen		6,045		—		5,688		—
Korean won						2,558		—
Taiwan dollar						1,861		—
Canadian dollar		3,672		—		1,507		—
Korean won		2,085		—
Mexican peso		—		1,447
Singapore dollar						1,173		—

Total	$	11,802	$	78,354	$	12,787	$	58,306

Interest Rate Risk. We have no material exposure to market risk for changes in interest rates. We invest any excess cash primarily in depository accounts and money market funds, and changes in interest rates would not be material to our financial condition or results of operations. We enter into debt obligations principally to support general corporate purposes, including working capital requirements, capital expenditures and acquisitions. At ~~April 3, 2009,~~January 1, 2010, our debt obligations had fixed interest rates.

Based upon rates currently available to us for debt with similar terms and remaining maturities, the carrying amounts of long-term debt approximate their estimated fair values. Although payments under certain of our operating leases for our facilities are tied to market indices, we are not exposed to material interest rate risk associated with our operating leases.

Principal Amounts and Related Weighted-Average Interest Rates By Year of Maturity


	Six Months Ending Oct. 2, 2009			Fiscal Years																					Nine Months Ending Oct. 1, 2010			Fiscal Years																		Total
	Six Months Ending Oct. 2, 2009			2010			2011			2012			2013			2014			Thereafter			Total			Nine Months Ending Oct. 1, 2010			2011			2012			2013			2014			2015			Thereafter			Total
(in thousands)
Long-term debt	$	—		$	6,250		$	—		$	6,250		$	—		$	6,250		$	—		$	18,750
Long-term debt (including current portion)																									$	6,250		$	—		$	6,250		$	—		$	6,250		$	—		$	—		$	18,750
Average interest rate		—	%		6.7	%		—	%		6.7	%		—	%		6.7	%		—	%		6.7	%		6.7	%		—	%		6.7	%		—	%		6.7	%		—	%		—	%		6.7	%

Defined Benefit Retirement Plans. Most of our retirement plans, including all U.S.-based plans, are defined contribution plans. However, we also provide defined benefit pension plans in certain countries outside of the U.S. Our obligations under these defined benefit plans will ultimately be settled in the future and are therefore subject to estimation. Defined benefit pension accounting under ~~SFAS 87,~~~~Employers’~~FASB Accounting ~~for Pensions~~Standard Codification (“ASC”) 715-30,Defined Benefit Plans-Pension,, is intended to reflect the recognition of future benefit costs over the employees’ estimated service periods based on the terms of the pension plans and ~~the~~our investment and funding ~~decisions made by us.~~decisions.

For our defined benefit pension plans, we make assumptions regarding several variables including the expected long-term rate of return on plan assets and the discount rate in order to determine defined benefit pension plan expense for the year. This expense is referred to as “net periodic pension cost.” We assess the expected long-term rate of return on plan assets and discount rate assumption for each defined benefit plan based on relevant market conditions ~~as prescribed by SFAS 87~~ and make adjustments to the assumptions as appropriate. On an annual basis, we analyze the rates of return on plan assets and discount rates used and determine that these rates are reasonable. For rates of return, this analysis is based on a review of the nature of the underlying assets,

the allocation of those assets and their historical performance and expectations relative to relevant markets in the countries where the related plans are effective. Historically, our assumed asset allocations have not varied significantly from the actual allocations. Discount rates are based on the prevailing market long-term interest rates in the countries where the related plans are effective. As of October ~~3, 2008,~~2, 2009, the estimated long-term rate of return on our defined benefit pension plan assets ranged from ~~0.8%~~0.3% to ~~7.1%~~6.5% (weighted-average of ~~5.8%~~5.1%), and the assumed discount rate for our defined benefit pension plan obligations ranged from ~~2.0%~~1.8% to ~~6.1%~~5.6% (weighted-average of ~~6.0%~~5.4%).

If any of these assumptions were to change, our net periodic pension cost would also change. We incurred net periodic pension cost relating to our defined benefit pension plans of $1.4 million in fiscal year 2009, $1.5 million in fiscal year 2008 ~~$2.3 million in fiscal year 2007~~ and $2.3 million in fiscal year ~~2006,~~2007, and expect our net periodic pension cost to be approximately ~~$1.4~~$1.2 million in fiscal year ~~2009.~~2010. A ~~one percent~~100 basis point decrease in the weighted-average estimated return on plan assets or assumed discount rate would increase our net periodic pension cost for fiscal year ~~2009~~2010 by ~~$1.0~~$0.4 million or ~~$0.4~~$0.5 million, respectively. As of October ~~3, 2008,~~2, 2009, our projected benefit obligation relating to defined benefit pension plans was ~~$47.7~~$50.6 million. A ~~one percent~~100 basis point decrease in the weighted-average estimated discount rate would increase this obligation by ~~$9.8~~$10.3 million.

During the second quarter of fiscal year 2009, the Company ceased future benefit accruals to a defined benefit pension plan in the United Kingdom. In connection with this action, the Company recorded a curtailment loss of $0.1 million during the second quarter of fiscal year 2009.

Disclosure Controls and Procedures. Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our Chief Executive Officer and the Chief Financial Officer have concluded that as of the end of the period covered by this Quarterly Report on Form 10-Q (for the period ended ~~April 3, 2009)~~January 1, 2010), our disclosure controls and procedures were effective.

Inherent Limitations on the Effectiveness of Controls. The Company’s management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons or by collusion of two or more people. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Control over Financial Reporting. There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the ~~second~~first quarter of our fiscal year ~~2009~~2010 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

See Part I, Item 3—Legal Proceedings in Amendment No. 1 on Form 10-K/A for the fiscal year ended October 2, 2009, which Amendment was filed with the SEC on January 29, 2010.

See Item 1A—Risk Factors presented in our Annual Report on Form 10-K for the fiscal year ended October ~~3, 2008,~~2, 2009, which we encourage you to carefully consider.

(c) During the fiscal quarter ended January 1, 2010 ~~February 2008 Stock Repurchase Program~~,~~. The following table summarizes information relating~~ the Company repurchased and retired 4,000 shares tendered to ~~our stock repurchases during~~it by employees in settlement of employee tax withholding obligations due from those employees upon the ~~second quarter~~vesting of ~~fiscal year 2009:~~restricted stock.


Delaware		77-0501995
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

3120 Hansen Way, Palo Alto, California		94304-1030
(Address of Principal Executive Offices)		(Zip Code)


Large accelerated filer x		Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)		Smaller reporting company ¨


		Page
PART I	Financial Information

Item 1.	Financial Statements:

	Unaudited Condensed Consolidated Statement of Earnings	3

	Unaudited Condensed Consolidated Balance Sheet	4

	Unaudited Condensed Consolidated Statement of Cash Flows	5

	Notes to the Unaudited Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2520

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	4228

Item 4.	Controls and Procedures	4429

PART II	Other Information

Item 1.	Legal Proceedings	31

Item 1A.	Risk Factors	4531

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	45

~~Item 4.~~	~~Submission of Matters to a Vote of Security Holders~~	4531

Item 6.	Exhibits	4631


	Fiscal Quarter Ended						Six Months Ended
	April 3, 2009			March 28, 2008			April 3, 2009			March 28, 2008
Sales
Products	$	172,613		$	214,648		$	348,467		$	418,823
Services		32,813			33,517			65,195			66,773

Total sales		205,426			248,165			413,662			485,596

Cost of sales
Products		97,436			115,953			191,959			227,110
Services		18,466			19,336			36,858			38,308

Total cost of sales		115,902			135,289			228,817			265,418

Gross profit		89,524			112,876			184,845			220,178

Operating expenses
Selling, general and administrative		59,278			67,603			120,194			133,583
Research and development		14,745			18,190			29,259			35,370

Total operating expenses		74,023			85,793			149,453			168,953

Operating earnings		15,501			27,083			35,392			51,225
Impairment of private company equity investment (Note 15)		—			(3,018	)		—			(3,018	)
Interest income		338			1,751			925			3,688
Interest expense		(335	)		(435	)		(657	)		(884	)

Earnings before income taxes		15,504			25,381			35,660			51,011
Income tax expense		5,318			9,594			12,433			17,640

Net earnings	$	10,186		$	15,787		$	23,227		$	33,371


Net earnings per share:
Basic	$	0.35		$	0.53		$	0.81		$	1.11

Diluted	$	0.35		$	0.52		$	0.80		$	1.09

Shares used in per share calculation:
Basic		28,853			29,830			28,853			30,080

Diluted		28,952			30,243			28,963			30,598


	Fiscal Quarter Ended
	January 1, 2010			January 2, 2009
Sales
Products	$	166,587		$	175,854
Services		34,593			32,382

Total sales		201,180			208,236

Cost of sales
Products		94,588			94,523
Services		19,715			18,392

Total cost of sales		114,303			112,915

Gross profit		86,877			95,321

Operating expenses
Selling, general and administrative		59,877			60,916
Research and development		14,546			14,514

Total operating expenses		74,423			75,430

Operating earnings		12,454			19,891
Interest income		530			587
Interest expense		(333	)		(322	)

Earnings before income taxes		12,651			20,156
Income tax expense		4,580			7,115

Net earnings	$	8,071		$	13,041


Net earnings per share:
Basic	$	0.28		$	0.45

Diluted	$	0.28		$	0.45

Shares used in per share calculation:
Basic		28,863			28,854

Diluted		29,246			28,950


Acquired Company/Business	Remaining Amount Available (maximum)		Measurement Period	Measurement Period End Date
	(in ~~millions)~~millions	)
Oxford Diffraction Limited	$ 7.0		3 years	April 2011
Analogix Business	~~2.7~~2.8		3 years	December 2010
Other	~~0.6~~0.3		2 years	July 2010

Total	$~~10.3~~10.1


	Scientific Instruments			Vacuum Technologies		Total Company
(in thousands)
Balance as of October 3, 2008	$	217,242		$	966	$	218,208
Contingent payments on prior-year acquisitions		1,591			—		1,591
Foreign currency impacts and other adjustments		(16,226	)		—		(16,226	)

Balance as of April 3, 2009	$	202,607		$	966	$	203,573


	October 3, 2008
	Gross		Accumulated Amortization			Net
(in thousands)
Intangible assets
Existing technology	$	16,503	$	(9,699	)	$	6,804
Patents and core technology		40,680		(14,253	)		26,427
Trade names and trademarks		2,425		(1,946	)		479
Customer lists		13,090		(10,278	)		2,812
Other		2,972		(2,522	)		450

Total	$	75,670	$	(38,698	)	$	36,972


	Shares		Weighted Average Exercise Price		Aggregate Grant Date Fair Value ⁽¹⁾
	(in thousands)				(in millions)
Outstanding at October 3, 2008	1,660		$	44.21
Granted	334		$	35.44	$	3.6
Exercised	(26	)	$	9.77
Cancelled or expired	(34	)	$	44.81

Outstanding at April 3, 2009	1,934		$	43.15


	Shares		Weighted Average Grant Date Fair Value		Aggregate Grant Date Fair Value
	(in thousands)				(in millions)
Outstanding and unvested at October 3, 2008	105		$	54.51
Granted⁽¹⁾	122		$	24.20	$	3.0
Vested⁽²⁾	(56	)	$	49.13
Forfeited	(3	)	$	53.56

Outstanding and unvested at April 3, 2009	168		$	34.37


	Shares		Weighted Average Grant Date Fair Value
	(in thousands)
Outstanding and unvested at October 2, 2009	156		$	32.51
Vested⁽¹⁾	(24	)	$	55.91
Forfeited	—		$	—

Outstanding and unvested at January 1, 2010	132		$	28.34


	Pretax Earnings						Pretax Earnings
	Fiscal Quarter Ended						Six Months Ended
	April 3, 2009			March 28, 2008			April 3, 2009			March 28, 2008
(in millions)
Scientific Instruments	$	12.4		$	22.5		$	28.8		$	42.3
Vacuum Technologies		6.7			8.8			13.7			16.5

Total industry segments		19.1			31.3			42.5			58.8
General corporate		(3.6	)		(4.2	)		(7.1	)		(7.6	)
Impairment of private company equity investment		—			(3.0	)		—			(3.0	)
Interest income		0.3			1.7			0.9			3.7
Interest expense		(0.3	)		(0.4	)		(0.6	)		(0.9	)

Total pretax earnings	$	15.5		$	25.4		$	35.7		$	51.0


Restructuring Plan		Estimated Annual Cost Savings
Fiscal Year 2007 Plan (Scientific Instruments - to combine and optimize the development and assembly on certain products and to centralize functions and reallocate resources to rapidly growing product lines)		$3 million - $5 million
Fiscal Year 2009 First Quarter Plan (Scientific Instruments - to reduce headcount and operating costs and increase operating margins)		$2 million - $3 million
Fiscal Year 2009 Second Quarter Plan (Scientific Instruments and Vacuum Technologies - to reduce its cost structure, ~~due to global economic uncertainties,~~ primarily through headcount reduction)		$20 million - $24 million


Acquired Company/Business	Remaining Amount Available (maximum) ~~(maximum)~~	Measurement Period	Measurement Period End Date
	(in millions)
Oxford Diffraction Limited	$ 7.0	3 years	April 2011
Analogix Business	~~2.7~~2.8	3 years	December 2010
Other	~~0.6~~0.3	2 years	July 2010

Total	$~~10.3~~10.1


Fiscal Month	Shares Repurchased ⁽¹⁾	Average Price Per Share⁽¹⁾		Total Value of Shares Repurchased as Part of Publicly Announced Plan^{(2) (3)}		Maximum Total Value Of Shares that May Yet Be Purchased Under the Plan
(in thousands, except per share amount)
Balance—January 2, 2009						$	44,649
January 3, 2009—January 30, 2009	—	$	—	$	—		—
January 31, 2009—February 27, 2009	—		—		—		—
February 28, 2009—April 3, 2009	347		20.69		7,100	$	37,549

Total shares repurchased	347	$	20.69	$	7,100


	Votes For	Votes Against	Votes Withheld	Abstentions
Proposal One—Election of Directors:
Nominee: Richard U. De Schutter	26,723,124	—	1,023,269	—
Nominee: James T. Glover	26,745,673	—	1,000,720	—

Proposal Two—Ratification of Appointment of PricewaterhouseCoopers LLP	27,472,745	245,854	—	27,793


		Incorporated by Reference			~~Filed~~ ~~Herewith~~
Exhibit No.	Exhibit Description	Form	Date	Exhibit Number

~~4.1~~	~~Specimen Common Stock Certificate.~~				XFiled Herewith

31.1	Certification of Chief Executive Officer Pursuant to ~~Section 302~~Rule 13a-14(a) of the ~~Sarbanes-Oxley~~Securities Exchange Act of ~~2002.~~1934, as amended.				X

31.2	Certification of Chief Financial Officer Pursuant to ~~Section 302~~Rule 13a-14(a) of the ~~Sarbanes-Oxley~~Securities Exchange Act of ~~2002.~~1934, as amended.				X

32.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of ~~2002.~~2002).

32.2	Certification of Chief Financial Officer Pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of ~~2002.~~2002).

VARIAN, INC.
(Registrant)

Date: ~~May 11, 2009~~February 5, 2010

/S/ G. EDWARD MCCLAMMY

G. Edward McClammy
Senior Vice President and Chief Financial Officer
(Duly Authorized Officer and
Principal Financial Officer)